



صندوق الأهلي للمتاجرة بأسهم الرعاية الصحية
AlAhli Health Care Trading Equity Fund

التقرير السنوي - 2020

Annual Report - 2020



Contents

المحتويات

- Investment Fund Information • معلومات صندوق الاستثمار
- Fund Performance • أداء الصندوق
- Fund Manager • مدير الصندوق
- Investment Activities • أنشطة الاستثمار
- Terms & Conditions Material Changes • تغيرات حدثت في الشروط والأحكام
- Custodian • أمين الحفظ
- Auditor • المحاسب القانوني
- Financial Statements • القوائم المالية



AlAhli Healthcare Trading Equity Fund

صندوق الأهلي للمتاجرة بأسهم الرعاية الصحية

Investment Fund Information

معلومات صندوق الاستثمار

Investment Objective

أهداف الاستثمار

AlAhli Healthcare Trading Equity Fund aims to achieve medium to long term capital growth by investing in globally listed equities of health care companies according to the Sharia Guidelines. The Fund seeks to achieve competitive returns during the medium to long term (3 years or more).

يهدف صندوق الأهلي للمتاجرة بأسهم الرعاية الصحية إلى نمو رأس المال على المدى المتوسط إلى الطويل من خلال الاستثمار في أسهم شركات الرعاية الصحية المدرجة عالمياً وفقاً للضوابط الشرعية. تتمثل أهداف الصندوق في تزويد المستثمرين بمعدلات عائد منافسة عبر الفترات متوسطة الأجل إلى طويلة الأجل (ثلاث سنوات أو أكثر).

Investment Policies

سياسات الاستثمار وممارساته

The Fund is actively managed, with investment focus the stocks of health care and health care related companies.

يدار الصندوق بطريقة نشطة، وتركز الصندوق استثماراته في أسهم شركات تقدم خدمات الرعاية الصحية والأنشطة ذات الصلة.

Distribution of Income & Gain Policy

سياسة توزيع الدخل والأرباح

Income and dividends will be reinvested in the Fund. No income or dividends will be distributed to Unitholders.

يتم إعادة استثمار الدخل والأرباح في الصندوق، ولا يتم توزيع أي دخل وأرباح على مالكي الوحدات.

- The fund's reports are available upon request free of charge.

- متاح تقارير الصندوق عند الطلب وبدون مقابل.

Fund Performance

أداء الصندوق

Fund performance for the last three years

أداء الصندوق للسنوات الثلاث الأخيرة:

Year	2020	2019	2018	السنة
Net Assets value (NAV)*	72,586,537.00	60,160,938	47,874,595	صافي قيمة الأصول*
NAV per Unit*	3.15	2.71	2.23	صافي قيمة الأصول لكل وحدة*
Highest NAV per Unit *	3.15	2.72	2.47	أعلى سعر وحدة*
Lowest NAV per Unit *	2.11	2.19	2.12	أقل سعر وحدة*
Number of Units	23,042,053	22,176,864	21,453,029	عدد الوحدات
Income Distribution per Unit	-	-	-	الأرباح الموزعة لكل وحدة
Fees & Expense Ratio	2.19%	2.02%	2.04%	إجمالي نسبة الرسوم والمصروفات

*In US Dollars

*بالدولار الأمريكي

Total return compared to the benchmark for 1 year, 3 years, and 5 years:

العائد الإجمالي للصندوق مقارنة بالمؤشر لسنة واحدة، وثلاث سنوات، خمس سنوات:

Period	5 Years – سنوات 5	3 Years - سنوات 3	1 Year - سنة	الفترة
Total Return %	7.13	12.16	16.12	عائد الصندوق %
Benchmark %	10.72	15.16	16.99	عائد المؤشر %

Annual total return for the fund last 10 years:

العائد الإجمالي السنوي للصندوق للعشر سنوات الماضية:

Year	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	السنة
Return %	16.12	21.56	-0.05	14.07	-12.34	4.44	16.30	34.89	16.47	1.25	العائد %
Benchmark %	16.99	26.62	3.09	17.78	-7.50	6.82	16.54	36.52	19.32	8.17	المؤشر %



Actual fees and fund expenses paid by the investment fund during the year as a percentage of average Net Asset Value:

مقابل الخدمات والعمولات والأتعاب التي تحملها الصندوق على مدار العام كنسبة مئوية من متوسط صافي قيمة أصول الصندوق:

Fees and Expenses	ألف دولار USD '000	النسبة المئوية %	الرسوم والمصروفات
Management Fee Expense	1162	1.85	رسوم الإدارة
VAT on Management Fee	137	0.28	ضريبة القيمة المضافة على رسوم الإدارة
Audit Fee Expense	10	0.01	مراجعة حسابات الصندوق
Fund Administration	14	0.02	العمليات الإدارية
CMA Fee	2	0.00	هيئة السوق المالية
Tadawul Fee	1.00	0.00	تداول
Custody Fees	5	0.01	رسوم الحفظ
Shariah Audit Fee Expense	8	0.01	المراجعة الشرعية
Fund Board Fee Expense	6	0.01	مجلس إدارة الصندوق
Dealing Fees	10.00	0.00	رسوم التعامل
Total Fees and Expenses	1355.00	2.19	مجموع الرسوم والمصاريف

Material Changes

No material changes occurred during the year.

تغيرات جوهرية حدثت خلال الفترة

لم تحدث أي تغييرات جوهرية تؤثر على أداء الصندوق

Exercising of voting rights

The Fund Manager has exercised voting rights, for more details kindly refer to the "Exercising of voting right Annex".

ممارسات التصويت السنوية

قام مدير الصندوق بممارسات التصويت السنوية. و للمزيد من التفاصيل يرجى مراجعة "ملحق ممارسات التصويت السنوية".

Fund Board Annual Report

The Board of Directors consists of the following members, who were appointed by the fund manager and approved by the Capital Market Authority:

Mohammed Al-Ali	Chairman (Non-independent)
Mohammed AlSaggaf	Non-independent member
Asem AlHomaidi	Independent member
Mohammed AlOyaidi	Independent member

تقرير مجلس إدارة الصندوق السنوي

يتكون مجلس إدارة الصندوق من الأعضاء التاليين، والذين تعيينهم من قبل مدير الصندوق بعد موافقة هيئة السوق المالية:

محمد عبدالله العلي	رئيس مجلس إدارة الصندوق (عضو غير مستقل)
محمد جعفر السقاف	عضو غير مستقل
الدكتور/ عاصم خالد الحميضي	عضو مستقل
محمد عمر العبيدي	عضو مستقل

The Fund's Board of Directors held three meetings during 2020. The following is a summary of the key decisions approved and the matters discussed by the Fund's Board of Directors:

- Fund's objectives achievement and performance review
- Risks related to the funds; including: liquidity, market, operational risks.
- Ensuring fund's compliance to all applicable rules and regulations.

عقد مجلس إدارة الصندوق ثلاثة اجتماعات خلال العام 2020م، وفيما يلي ملخصاً لأهم القرارات التي تم إقرارها والمواضيع التي تمت مناقشتها من قبل مجلس إدارة الصندوق:

- مناقشة تحقيق الصندوق لأهدافه وأدائه خلال العام
- المخاطر المتعلقة بالصندوق بما في ذلك مخاطر السيولة، السوق، والتشغيل.
- التزام الصناديق بلوائح هيئة السوق المالية مع مسؤول المطابقة والالتزام.

Fund Manager

NCB Capital Company, Saudi Arabia
Tower B, King Saud Road, P.O. Box 22216, Riyadh 11495
Tel: +966 920000232
Website: www.alahlicapital.com

مدير الصندوق

شركة الأهلي المالية، المملكة العربية السعودية
البرج ب، طريق الملك سعود، ص.ب. 22216، الرياض 11495
هاتف: +966 920000232
الموقع: www.alahlicapital.com



Sub-Manager / Investment Adviser

مدير الصندوق من الباطن و/أو مستشارين الاستثمار

TCW Asset Management Company

865 South Figueroa Street, Suite 1800, Los Angeles, CA 9001

Investment Activities

During the year the fund maintained an overweight in Biotechnology and Health Care Technology Sectors, and investing Pharmaceuticals companies who were working on finding vaccines for COVID-19 virus.

أنشطة الاستثمار
خلال عام 2020م، ركّز الصندوق على قطاعي التكنولوجيا الحيوية وتكنولوجيا الرعاية الصحية والاستثمار في الشركات و زاد تركيز الاستثمار في أسهم شركات صناعة الأدوية التي تعمل على إيجاد لقاح لفيروس كورونا (كوفيد-19).

Performance

Fund Performance 16.12%
Benchmark Performance 16.99%

أداء الصندوق 16.12%
أداء المؤشر 16.99%

The fund underperformed the benchmark by 87 bps.

انخفض أداء الصندوق عن أداء المؤشر بفارق 87 نقطة أساس.

Terms & Conditions and information memorandum Material Changes

There are no changes in the terms and condition, and Information Memorandum.

تغيرات حدثت في شروط وأحكام الصندوق و مذكرة المعلومات

لا توجد تغيرات في الشروط والأحكام ومذكرة المعلومات.

Other information enabling unitholders to make informed judgment about fund activities during the period

None

معلومات أخرى بشأن أنشطة الصندوق خلال الفترة تمكن مالك الوحدات من اتخاذ قرار مدروس

لا يوجد

Investments in other Investment Funds

The fund does not invest substantially in other investment funds.

الاستثمار في صناديق استثمارية أخرى

الصندوق لم يستثمر بشكل كبير في صناديق استثمارية أخرى.

Special Commission

The fund benefited of soft dollar commission to access related research.

عمولات خاصة

استفاد الصندوق من عمولات المحفظة من أجل الحصول على بحوث ذات صلة.

Conflict of Interests

None

تعارض في المصالح

لا يوجد

Fund Distribution During The Year

None

توزيعات الصندوق خلال العام

لا يوجد

Incorrect Valuation or Pricing

None

خطأ في التقويم والتسعير

لا يوجد

Investment Limitation Breaches

There were no breaches to any of the Investment Restrictions, Limitations and borrowing powers applicable to IFR.

مخالفة قيود الاستثمار

لم تتم مخالفة أي من قيود و حدود الاستثمار وصلاحيات الاقتراض المعمول بها في لائحة صناديق الاستثمار.

Custodian

The Northern Trust Company of Saudi Arabia
Nakheel Tower, P.O. Box 10175, Riyadh 11433, Saudi Arabia
Tel: +966114188694

Website: www.northerntrust.com

أمين الحفظ
شركة نورذن ترست العربية السعودية
برج النخيل، ص.ب. 10175، الرياض 11433، المملكة العربية السعودية
هاتف: +966114188694
الموقع: www.northerntrust.com

Custodian's duties and responsibilities

- The custodian shall be held responsible for compliance with investment funds Regulations whether he performed his duties directly or delegated to any third party. The custodian shall be held responsible to the fund manager and unitholder for any losses caused to the investment fund due to the custodian fraud, negligence, misconduct or willful default.
- The custodian shall be responsible for taking custody and protecting the fund's assets on behalf of unitholders, and taking all necessary administrative measures in relation to the custody of the fund's assets.
- The Fund Manager acknowledges that the responsibilities vested in the custodian does not include ensuring the fund manager's compliance with the contents of subparagraphs (a,b,c) of paragraph (d-3) of annex 5 of the Investment Funds Regulations "IFR".

واجبات ومسؤوليات أمين الحفظ

- يعد أمين الحفظ مسؤولاً عن التزاماته وفقاً لأحكام لائحة صناديق الاستثمار، سواء أدى مسؤولياته بشكل مباشر أم كلف بها طرفاً ثالثاً بموجب أحكام لائحة صناديق الاستثمار أو لائحة مؤسسات السوق المالية. ويُعدّ أمين الحفظ مسؤولاً تجاه مدير الصندوق ومالكي الوحدات عن خسائر الصندوق الناجمة بسبب احتيال أو إهمال أو سوء تصرف أو تقصيره المتعمد.
- يعد أمين الحفظ مسؤولاً عن حفظ أصول الصندوق وحمايتها لصالح مالكي الوحدات، وهو مسؤول كذلك عن اتخاذ جميع الإجراءات الإدارية اللازمة فيما يتعلق بحفظ أصول الصندوق.
- يقر مدير الصندوق بأن المسؤوليات المنوطة بأمين الحفظ لا تشمل إبداء رأيه حول ما إذا كان مدير الصندوق قد قام بالأنشطة في الفقرات الفرعية (أ،ب،ج) من الفقرة (د-3) من الملحق (5) من لائحة صناديق الاستثمار.

Fund Manager Opinion

- Units were Issued, transferred and redeemed in accordance with the provision of the IFR and fund Terms and Conditions
- Units were valued and calculated in accordance with the provisions of IFR, Fund and fund Terms and Conditions.
- There were no breaches to any of the Investment Restrictions, Limitations and borrowing powers applicable to IFR.

رأي مدير الصندوق

- تم إصدار ونقل واسترداد الوحدات بموجب أحكام لائحة صناديق الاستثمار وشروط وأحكام الصندوق.
- تم تقويم وحساب سعر الوحدات بموجب أحكام لائحة صناديق الاستثمار وشروط وأحكام الصندوق.
- لم تتم مخالفة أي من قيود و حدود الاستثمار وصلاحيات الاقتراض المعمول بها في لائحة صناديق الاستثمار.

Auditor

KPMG Al Fozan & Partners
Zahran Business Center, Prince Sultan Street, P.O Box 55078
21534 Jeddah, Saudi Arabia
Tel: +966 12 6989595
Website: www.kpmg.com/sa

المحاسب القانوني

كي بي ام جي الفوزان وشركاه
مركز زهران للأعمال – شارع الأمير سلطان ص.ب 55078،
جدة 21534 المملكة العربية السعودية،
هاتف: +966 12 698 9595
الموقع: www.kpmg.com/sa

Auditor's Opinion

Accompanying financial statements have complied with the requirements of the applicable provisions of the Investment Funds Regulations issued by the Capital Market Authority, and the Fund's Terms and Conditions and the Information Memorandum in so far as they affect the preparation of the financial statements and accordingly nothing has been reported by the auditor in their report which is in compliance with the SOCPA requirements.

رأي المحاسب القانوني

إن القوائم المالية المرفقة لهذا التقرير متوافقة مع متطلبات لائحة صناديق الاستثمار الصادرة عن هيئة السوق المالية، وشروط وأحكام الصندوق ومذكر معلوماته فيما يتعلق بإعداد القوائم المالية، ولم يوجد ما يتطلب الإبلاغ عنه من قبل مراجع الحسابات في تقريره حسب متطلبات الهيئة السعودية للمحاسبين القانونيين.



Annex - Exercised Voting Rights

ملحق - ممارسات التصويت السنوية

Company Name	Meeting Date	Proposal Text	Vote Instruction
Novartis AG	2/28/2020	Accounts and Reports	Take No Action
Novartis AG	2/28/2020	Ratification of Board and Management Acts	Take No Action
Novartis AG	2/28/2020	Allocation of Profits/Dividends	Take No Action
Novartis AG	2/28/2020	Cancellation of Shares and Reduction in Share Capital	Take No Action
Novartis AG	2/28/2020	Board Compensation	Take No Action
Novartis AG	2/28/2020	Executive Compensation	Take No Action
Novartis AG	2/28/2020	Compensation Report	Take No Action
Novartis AG	2/28/2020	Elect Jörg Reinhardt as Board Chair	Take No Action
Novartis AG	2/28/2020	Elect Nancy C. Andrews	Take No Action
Novartis AG	2/28/2020	Elect Ton Büchner	Take No Action
Novartis AG	2/28/2020	Elect Patrice Bula	Take No Action
Novartis AG	2/28/2020	Elect Srikanth M. Datar	Take No Action
Novartis AG	2/28/2020	Elect Elizabeth Doherty	Take No Action
Novartis AG	2/28/2020	Elect Ann M. Fudge	Take No Action
Novartis AG	2/28/2020	Elect Frans van Houten	Take No Action
Novartis AG	2/28/2020	Elect Andreas von Planta	Take No Action
Novartis AG	2/28/2020	Elect Charles L. Sawyers	Take No Action
Novartis AG	2/28/2020	Elect Enrico Vanni	Take No Action
Novartis AG	2/28/2020	Elect William T. Winters	Take No Action
Novartis AG	2/28/2020	Elect Bridgette P. Heller	Take No Action
Novartis AG	2/28/2020	Elect Simon Moroney	Take No Action
Novartis AG	2/28/2020	Elect Patrice Bula as Compensation Committee Member	Take No Action
Novartis AG	2/28/2020	Elect Srikanth M. Datar as Compensation Committee Member	Take No Action
Novartis AG	2/28/2020	Elect Enrico Vanni as Compensation Committee Member	Take No Action
Novartis AG	2/28/2020	Elect William T. Winters as Compensation Committee Member	Take No Action
Novartis AG	2/28/2020	Elect Bridgette P. Heller as Compensation Committee Member	Take No Action
Novartis AG	2/28/2020	Appointment of Auditor	Take No Action
Novartis AG	2/28/2020	Appointment of Independent Proxy	Take No Action
Novartis AG	2/28/2020	Additional or Amended Proposals	Take No Action
Agilent Technologies Inc.	3/18/2020	Elect Heidi K. Kunz	For
Agilent Technologies Inc.	3/18/2020	Elect Sue H. Rataj	For
Agilent Technologies Inc.	3/18/2020	Elect George A. Scangos	For
Agilent Technologies Inc.	3/18/2020	Elect Dow R. Wilson	For
Agilent Technologies Inc.	3/18/2020	Approval of the 2020 Employee Stock Purchase Plan	For
Agilent Technologies Inc.	3/18/2020	Advisory Vote on Executive Compensation	For
Agilent Technologies Inc.	3/18/2020	Ratification of Auditor	For
Novo Nordisk	3/26/2020	Accounts and Reports	For
Novo Nordisk	3/26/2020	Directors' Fees 2019	For



Novo Nordisk	3/26/2020	Directors' Fees 2020	For
Novo Nordisk	3/26/2020	Remuneration Policy	For
Novo Nordisk	3/26/2020	Amendments to Articles Regarding Agenda	For
Novo Nordisk	3/26/2020	Allocation of Profits/Dividends	For
Novo Nordisk	3/26/2020	Elect Helge Lund	For
Novo Nordisk	3/26/2020	Elect Jeppe Christiansen	For
Novo Nordisk	3/26/2020	Elect Brian Daniels	For
Novo Nordisk	3/26/2020	Elect Laurence Debroux	For
Novo Nordisk	3/26/2020	Elect Andreas Fibig	For
Novo Nordisk	3/26/2020	Elect Sylvie Grégoire	For
Novo Nordisk	3/26/2020	Elect Liz Hewitt	For
Novo Nordisk	3/26/2020	Elect Kasim Kutay	For
Novo Nordisk	3/26/2020	Elect Martin Mackay	For
Novo Nordisk	3/26/2020	Appointment of Auditor	For
Novo Nordisk	3/26/2020	Authority to Reduce Share Capital	For
Novo Nordisk	3/26/2020	Authority to Repurchase Shares	For
Novo Nordisk	3/26/2020	Authority to Issue Shares w/o Preemptive Rights For Employees	For
Novo Nordisk	3/26/2020	Authority to Issue Shares w/ Preemptive Rights for Existing Shareholder	For
Novo Nordisk	3/26/2020	Authority to Issue Shares w/o Preemptive Rights for Existing Shareholders	For
Novo Nordisk	3/26/2020	Charitable Donations	For
Novo Nordisk	3/26/2020	Shareholder's Proposal Regarding Information Disclosure on Remuneration.	Against
Chugai Pharmaceutical Co Ltd	3/30/2020	Allocation of Profits/Dividends	For
Chugai Pharmaceutical Co Ltd	3/30/2020	Elect Tatsuro Kosaka	For
Chugai Pharmaceutical Co Ltd	3/30/2020	Elect Motoo Ueno	For
Chugai Pharmaceutical Co Ltd	3/30/2020	Elect Osamu Okuda	For
Chugai Pharmaceutical Co Ltd	3/30/2020	Elect Mariko Momoi	For
Chugai Pharmaceutical Co Ltd	3/30/2020	Elect Takaaki Nimura	For
Chugai Pharmaceutical Co Ltd	3/30/2020	Elect Kenichi Masuda	For
Chugai Pharmaceutical Co Ltd	3/30/2020	Statutory Auditors' Fees	For
Otsuka Holdings Co.,Ltd.	3/27/2020	Elect Ichiro Otsuka	For
Otsuka Holdings Co.,Ltd.	3/27/2020	Elect Tatsuo Higuchi	For
Otsuka Holdings Co.,Ltd.	3/27/2020	Elect Yoshiro Matsuo	For
Otsuka Holdings Co.,Ltd.	3/27/2020	Elect Yuko Makino	For
Otsuka Holdings Co.,Ltd.	3/27/2020	Elect Shuichi Takagi	For
Otsuka Holdings Co.,Ltd.	3/27/2020	Elect Sadanobu Tobe	For
Otsuka Holdings Co.,Ltd.	3/27/2020	Elect Masayuki Kobayashi	For
Otsuka Holdings Co.,Ltd.	3/27/2020	Elect Noriko Tojo	For
Otsuka Holdings Co.,Ltd.	3/27/2020	Elect Makoto Inoue	For
Otsuka Holdings Co.,Ltd.	3/27/2020	Elect Yukio Matsutani	For
Otsuka Holdings Co.,Ltd.	3/27/2020	Elect Ko Sekiguchi	For
Otsuka Holdings Co.,Ltd.	3/27/2020	Elect Yoshihisa Aoki	For
Otsuka Holdings Co.,Ltd.	3/27/2020	Elect Mayo Mita	For
Johnson & Johnson	4/23/2020	Elect Mary C. Beckerle	For
Johnson & Johnson	4/23/2020	Elect D. Scott Davis	For
Johnson & Johnson	4/23/2020	Elect Ian E.L. Davis	For
Johnson & Johnson	4/23/2020	Elect Jennifer A. Doudna	For
Johnson & Johnson	4/23/2020	Elect Alex Gorsky	For
Johnson & Johnson	4/23/2020	Elect Marillyn A. Hewson	For
Johnson & Johnson	4/23/2020	Elect Hubert Joly	For



Johnson & Johnson	4/23/2020	Elect Mark B. McClellan	For
Johnson & Johnson	4/23/2020	Elect Anne M. Mulcahy	For
Johnson & Johnson	4/23/2020	Elect Charles Prince	For
Johnson & Johnson	4/23/2020	Elect A. Eugene Washington	For
Johnson & Johnson	4/23/2020	Elect Mark A. Weinberger	For
Johnson & Johnson	4/23/2020	Elect Ronald A. Williams	For
Johnson & Johnson	4/23/2020	Advisory Vote on Executive Compensation	For
Johnson & Johnson	4/23/2020	Ratification of Auditor	For
Johnson & Johnson	4/23/2020	Removal of Directors Without Cause	For
Johnson & Johnson	4/23/2020	Shareholder Proposal Regarding Independent Chair	For
Johnson & Johnson	4/23/2020	Shareholder Proposal Regarding Report on Response to Opioid Epidemic	For
Astrazeneca plc	4/29/2020	Accounts and Reports	For
Astrazeneca plc	4/29/2020	Allocation of Profits/Dividends	For
Astrazeneca plc	4/29/2020	Appointment of Auditor	For
Astrazeneca plc	4/29/2020	Authority to Set Auditor's Fees	For
Astrazeneca plc	4/29/2020	Elect Leif Johansson	For
Astrazeneca plc	4/29/2020	Elect Pascal Soriot	For
Astrazeneca plc	4/29/2020	Elect Marc Dunoyer	For
Astrazeneca plc	4/29/2020	Elect Geneviève B. Berger	For
Astrazeneca plc	4/29/2020	Elect Philip Broadley	For
Astrazeneca plc	4/29/2020	Elect Graham A. Chipchase	For
Astrazeneca plc	4/29/2020	Elect Michel Demaré	For
Astrazeneca plc	4/29/2020	Elect Deborah DiSanzo Eldracher	For
Astrazeneca plc	4/29/2020	Elect Sheri McCoy	For
Astrazeneca plc	4/29/2020	Elect Tony SK MOK	For
Astrazeneca plc	4/29/2020	Elect Nazneen Rahman	For
Astrazeneca plc	4/29/2020	Elect Marcus Wallenberg	For
Astrazeneca plc	4/29/2020	Remuneration Report (Advisory)	For
Astrazeneca plc	4/29/2020	Remuneration Policy (Binding)	For
Astrazeneca plc	4/29/2020	Authorisation of Political Donations	For
Astrazeneca plc	4/29/2020	Authority to Issue Shares w/ Preemptive Rights	For
Astrazeneca plc	4/29/2020	Authority to Issue Shares w/o Preemptive Rights	For
Astrazeneca plc	4/29/2020	Authority to Issue Shares w/o Preemptive Rights (Specified Capital Investment)	For
Astrazeneca plc	4/29/2020	Authority to Repurchase Shares	For
Astrazeneca plc	4/29/2020	Authority to Set General Meeting Notice Period at 14 Days	Against
Astrazeneca plc	4/29/2020	2020 Performance Share Plan	For
Pfizer Inc.	4/23/2020	Elect Ronald E. Blaylock	For
Pfizer Inc.	4/23/2020	Elect Albert Bourla	For
Pfizer Inc.	4/23/2020	Elect W. Don Cornwell	For
Pfizer Inc.	4/23/2020	Elect Joseph J. Echevarria	For
Pfizer Inc.	4/23/2020	Elect Scott Gottlieb	For
Pfizer Inc.	4/23/2020	Elect Helen H. Hobbs	For
Pfizer Inc.	4/23/2020	Elect Susan Hockfield	For
Pfizer Inc.	4/23/2020	Elect James M. Kilts	For
Pfizer Inc.	4/23/2020	Elect Dan R. Littman	For
Pfizer Inc.	4/23/2020	Elect Shantanu Narayen	For
Pfizer Inc.	4/23/2020	Elect Suzanne Nora Johnson	For



Pfizer Inc.	4/23/2020	Elect James Quincey	For
Pfizer Inc.	4/23/2020	Elect James C. Smith	For
Pfizer Inc.	4/23/2020	Ratification of Auditor	For
Pfizer Inc.	4/23/2020	Advisory Vote on Executive Compensation	For
Pfizer Inc.	4/23/2020	Shareholder proposal regarding right to act by written consent	For
Pfizer Inc.	4/23/2020	Shareholder Proposal Regarding Proxy Access Bylaw Amendment	Against
Pfizer Inc.	4/23/2020	Shareholder Proposal Regarding Lobbying Report	Against
Pfizer Inc.	4/23/2020	Shareholder Proposal Regarding Independent Chair	For
Pfizer Inc.	4/23/2020	Shareholder Proposal Regarding Gender Pay Equity Report	Against
Pfizer Inc.	4/23/2020	Elect Susan Desmond-Hellmann	For
Abbott Laboratories	4/24/2020	Elect Robert J. Alpern	For
Abbott Laboratories	4/24/2020	Elect Roxanne S. Austin	For
Abbott Laboratories	4/24/2020	Elect Sally E. Blount	For
Abbott Laboratories	4/24/2020	Elect Robert B. Ford	For
Abbott Laboratories	4/24/2020	Elect Michelle A. Kumbier	For
Abbott Laboratories	4/24/2020	Elect Edward M. Liddy	For
Abbott Laboratories	4/24/2020	Elect Darren W. McDew	For
Abbott Laboratories	4/24/2020	Elect Nancy McKinstry	For
Abbott Laboratories	4/24/2020	Elect Phebe N. Novakovic	For
Abbott Laboratories	4/24/2020	Elect William A. Osborn	For
Abbott Laboratories	4/24/2020	Elect Daniel J. Starks	For
Abbott Laboratories	4/24/2020	Elect John G. Stratton	For
Abbott Laboratories	4/24/2020	Elect Glenn F. Tilton	For
Abbott Laboratories	4/24/2020	Elect Miles D. White	For
Abbott Laboratories	4/24/2020	Ratification of Auditor	For
Abbott Laboratories	4/24/2020	Advisory Vote on Executive Compensation	For
Abbott Laboratories	4/24/2020	Shareholder Proposal Regarding Lobbying Report	Against
Abbott Laboratories	4/24/2020	Shareholder Proposal Regarding Disclosure of Adjustments to Non-GAAP Metrics in Executive Compensation	Against
Abbott Laboratories	4/24/2020	Shareholder Proposal Regarding Shareholder Approval of Bylaw Amendments	Against
Abbott Laboratories	4/24/2020	Shareholder Proposal Regarding Simple Majority Vote	For
Intuitive Surgical Inc	4/23/2020	Elect Craig H. Barratt	For
Intuitive Surgical Inc	4/23/2020	Elect Joseph C. Beery	For
Intuitive Surgical Inc	4/23/2020	Elect Gary S. Guthart	For
Intuitive Surgical Inc	4/23/2020	Elect Amal M. Johnson	For
Intuitive Surgical Inc	4/23/2020	Elect Don R. Kania	For
Intuitive Surgical Inc	4/23/2020	Elect Amy L. Ladd	For
Intuitive Surgical Inc	4/23/2020	Elect Keith R. Leonard, Jr.	For
Intuitive Surgical Inc	4/23/2020	Elect Alan J. Levy	For
Intuitive Surgical Inc	4/23/2020	Elect Jami Dover Nachtsheim	For
Intuitive Surgical Inc	4/23/2020	Elect Mark J. Rubash	For
Intuitive Surgical Inc	4/23/2020	Advisory Vote on Executive Compensation	For
Intuitive Surgical Inc	4/23/2020	Ratification of Auditor	For
Intuitive Surgical Inc	4/23/2020	Amendment to the 2010 Incentive Award Plan	For



Intuitive Surgical Inc	4/23/2020	Elimination of Supermajority Requirements	For
Intuitive Surgical Inc	4/23/2020	Approval of Shareholder Right to Call a Special Meeting	For
Sanofi	4/28/2020	Accounts and Reports; Non-Tax Deductible Expenses	For
Sanofi	4/28/2020	Consolidated Accounts and Reports	For
Sanofi	4/28/2020	Allocation of Profits/Dividends	For
Sanofi	4/28/2020	Special Auditors Report on Regulated Agreements	Against
Sanofi	4/28/2020	Ratification of the Co-option of Paul Hudson	For
Sanofi	4/28/2020	Elect Laurent Attal	For
Sanofi	4/28/2020	Elect Carole Piwnica	For
Sanofi	4/28/2020	Elect Diane Souza	For
Sanofi	4/28/2020	Elect Thomas Südhof	For
Sanofi	4/28/2020	Elect Rachel Duan	For
Sanofi	4/28/2020	Elect Lise Kingo	For
Sanofi	4/28/2020	Directors' fees	For
Sanofi	4/28/2020	Remuneration Policy (Board of Directors)	For
Sanofi	4/28/2020	Remuneration Policy (Chair)	For
Sanofi	4/28/2020	Remuneration Policy (CEO)	For
Sanofi	4/28/2020	Remuneration Report	For
Sanofi	4/28/2020	Remuneration of Serge Weinberg, Chair	For
Sanofi	4/28/2020	Remuneration of Paul Hudson, CEO	For
Sanofi	4/28/2020	Remuneration of Olivier Brandicourt, Former CEO	For
Sanofi	4/28/2020	Authority to Repurchase and Reissue Shares	For
Sanofi	4/28/2020	Authorisation of Legal Formalities	For
Lilly(Eli) & Co	5/4/2020	Elect Michael L. Eskew	For
Lilly(Eli) & Co	5/4/2020	Elect William G. Kaelin, Jr.	For
Lilly(Eli) & Co	5/4/2020	Elect David A. Ricks	For
Lilly(Eli) & Co	5/4/2020	Elect Marshall S. Runge	For
Lilly(Eli) & Co	5/4/2020	Elect Karen Walker	For
Lilly(Eli) & Co	5/4/2020	Advisory Vote on Executive Compensation	For
Lilly(Eli) & Co	5/4/2020	Ratification of Auditor	For
Lilly(Eli) & Co	5/4/2020	Repeal of Classified Board	For
Lilly(Eli) & Co	5/4/2020	Elimination of Supermajority Requirement	For
Lilly(Eli) & Co	5/4/2020	Shareholder Proposal Regarding Lobbying Report	Against
Lilly(Eli) & Co	5/4/2020	Shareholder Proposal Regarding Forced Swim Test	For
Lilly(Eli) & Co	5/4/2020	Shareholder Proposal Regarding Independent Chair	For
Lilly(Eli) & Co	5/4/2020	Shareholder Proposal Regarding Disclosure of Board Qualifications	Against
Lilly(Eli) & Co	5/4/2020	Shareholder Proposal Regarding Report on Linking Executive Compensation to Public Concern Over Drug Pricing	Against
Lilly(Eli) & Co	5/4/2020	Shareholder Proposal Regarding Bonus Deferral Policy	Against
Lilly(Eli) & Co	5/4/2020	Shareholder Proposal Regarding Recoupment Report	Against
Abbvie Inc	5/8/2020	Elect Robert J. Alpern	For
Abbvie Inc	5/8/2020	Elect Edward M. Liddy	For



Abbvie Inc	5/8/2020	Elect Melody B. Meyer	For
Abbvie Inc	5/8/2020	Elect Frederick H. Waddell	For
Abbvie Inc	5/8/2020	Ratification of Auditor	For
Abbvie Inc	5/8/2020	Advisory Vote on Executive Compensation	For
Abbvie Inc	5/8/2020	Elimination of Supermajority Requirement	For
Abbvie Inc	5/8/2020	Shareholder Proposal Regarding Lobbying Report	Against
Abbvie Inc	5/8/2020	Shareholder Proposal Regarding Independent Chair	For
Abbvie Inc	5/8/2020	Shareholder Proposal Regarding Report on Linking Executive Compensation to Public Concern Over Drug Pricing	Against
West Pharmaceutical Services, Inc.	5/5/2020	Elect Mark A. Buthman	For
West Pharmaceutical Services, Inc.	5/5/2020	Elect William F. Feehery	For
West Pharmaceutical Services, Inc.	5/5/2020	Elect Robert F. Friel	For
West Pharmaceutical Services, Inc.	5/5/2020	Elect Eric M. Green	For
West Pharmaceutical Services, Inc.	5/5/2020	Elect Thomas W. Hofmann	For
West Pharmaceutical Services, Inc.	5/5/2020	Elect Paula A. Johnson	For
West Pharmaceutical Services, Inc.	5/5/2020	Elect Deborah L. V. Keller	For
West Pharmaceutical Services, Inc.	5/5/2020	Elect Myla P. Lai-Goldman	For
West Pharmaceutical Services, Inc.	5/5/2020	Elect Douglas A. Michels	For
West Pharmaceutical Services, Inc.	5/5/2020	Elect Paolo Pucci	For
West Pharmaceutical Services, Inc.	5/5/2020	Elect Patrick J. Zenner	For
West Pharmaceutical Services, Inc.	5/5/2020	Advisory Vote on Executive Compensation	For
West Pharmaceutical Services, Inc.	5/5/2020	Increase of Authorized Common Stock	For
West Pharmaceutical Services, Inc.	5/5/2020	Ratification of Auditor	For
Baxter International Inc.	5/5/2020	Elect José E. Almeida	For
Baxter International Inc.	5/5/2020	Elect Thomas F. Chen	For
Baxter International Inc.	5/5/2020	Elect John D. Forsyth	For
Baxter International Inc.	5/5/2020	Elect James R. Gavin III	For
Baxter International Inc.	5/5/2020	Elect Peter S. Hellman	For
Baxter International Inc.	5/5/2020	Elect Michael F. Mahoney	For
Baxter International Inc.	5/5/2020	Elect Patricia Morrison	For
Baxter International Inc.	5/5/2020	Elect Stephen N. Oesterle	For
Baxter International Inc.	5/5/2020	Elect Cathy R. Smith	For
Baxter International Inc.	5/5/2020	Elect Thomas T. Stallkamp	For
Baxter International Inc.	5/5/2020	Elect Albert P.L. Stroucken	For
Baxter International Inc.	5/5/2020	Elect Amy M. Wendell	For
Baxter International Inc.	5/5/2020	Advisory Vote on Executive Compensation	For
Baxter International Inc.	5/5/2020	Ratification of Auditor	For
Baxter International Inc.	5/5/2020	Shareholder Proposal Regarding Independent Chair	For
Baxter International Inc.	5/5/2020	Shareholder Proposal Regarding Right to Act by Written Consent	For
Stryker Corp.	5/5/2020	Elect Mary K. Brainerd	For
Stryker Corp.	5/5/2020	Elect Srikanth M. Datar	For
Stryker Corp.	5/5/2020	Elect Roch Doliveux	For
Stryker Corp.	5/5/2020	Elect Allan C. Golston	For
Stryker Corp.	5/5/2020	Elect Kevin A. Lobo	For
Stryker Corp.	5/5/2020	Elect Sherilyn S. McCoy	For
Stryker Corp.	5/5/2020	Elect Andrew K. Silvernail	For
Stryker Corp.	5/5/2020	Elect Lisa M. Skeete Tatum	For
Stryker Corp.	5/5/2020	Elect Ronda E. Stryker	For



Stryker Corp.	5/5/2020	Elect Rajeev Suri	For
Stryker Corp.	5/5/2020	Ratification of Auditor	For
Stryker Corp.	5/5/2020	Advisory Vote on Executive Compensation	For
Stryker Corp.	5/5/2020	Shareholder Proposal Regarding Report on Non-Management Employee Representation on the Board	Against
Edwards Lifesciences Corp	5/7/2020	Elect Michael A. Mussallem	For
Edwards Lifesciences Corp	5/7/2020	Elect Kieran T. Gallahue	For
Edwards Lifesciences Corp	5/7/2020	Elect Leslie S. Heisz	For
Edwards Lifesciences Corp	5/7/2020	Elect William J. Link	For
Edwards Lifesciences Corp	5/7/2020	Elect Steven R. Loranger	For
Edwards Lifesciences Corp	5/7/2020	Elect Martha H. Marsh	For
Edwards Lifesciences Corp	5/7/2020	Elect Ramona Sequeira	For
Edwards Lifesciences Corp	5/7/2020	Elect Nicholas J. Valeriani	For
Edwards Lifesciences Corp	5/7/2020	Advisory Vote on Executive Compensation	For
Edwards Lifesciences Corp	5/7/2020	Approval of the 2020 Non-Employee Directors Stock Incentive Plan	For
Edwards Lifesciences Corp	5/7/2020	Increase of Authorized Common Stock for Stock Split	For
Edwards Lifesciences Corp	5/7/2020	Ratification of Auditor	For
Edwards Lifesciences Corp	5/7/2020	Shareholder Proposal Regarding Right to Act by Written Consent	For
Danaher Corp.	5/5/2020	Elect Linda P. Hefner Filler	For
Danaher Corp.	5/5/2020	Elect Thomas P. Joyce, Jr.	For
Danaher Corp.	5/5/2020	Elect Teri List-Stoll	For
Danaher Corp.	5/5/2020	Elect Walter G. Lohr, Jr.	For
Danaher Corp.	5/5/2020	Elect Jessica L. Mega	For
Danaher Corp.	5/5/2020	Elect Pardis C. Sabeti	For
Danaher Corp.	5/5/2020	Elect Mitchell P. Rales	For
Danaher Corp.	5/5/2020	Elect Steven M. Rales	For
Danaher Corp.	5/5/2020	Elect John T. Schwieters	For
Danaher Corp.	5/5/2020	Elect Alan G. Spoon	For
Danaher Corp.	5/5/2020	Elect Raymond C. Stevens	For
Danaher Corp.	5/5/2020	Elect Elias A. Zerhouni	For
Danaher Corp.	5/5/2020	Ratification of Auditor	For
Danaher Corp.	5/5/2020	Advisory Vote on Executive Compensation	For
Danaher Corp.	5/5/2020	Shareholder Proposal Regarding Right to Call Special Meetings	For
Boston Scientific Corp.	5/7/2020	Elect Nelda J. Connors	For
Boston Scientific Corp.	5/7/2020	Elect Charles J. Dockendorff	For
Boston Scientific Corp.	5/7/2020	Elect Yoshiaki Fujimori	For
Boston Scientific Corp.	5/7/2020	Elect Donna A. James	For
Boston Scientific Corp.	5/7/2020	Elect Edward J. Ludwig	For
Boston Scientific Corp.	5/7/2020	Elect Stephen P. MacMillan	For
Boston Scientific Corp.	5/7/2020	Elect Michael F. Mahoney	For
Boston Scientific Corp.	5/7/2020	Elect David J. Roux	For
Boston Scientific Corp.	5/7/2020	Elect John E. Sununu	For
Boston Scientific Corp.	5/7/2020	Elect Ellen M. Zane	For
Boston Scientific Corp.	5/7/2020	Advisory Vote on Executive Compensation	For
Boston Scientific Corp.	5/7/2020	Amendment to the 2011 Long-Term Incentive Plan	For
Boston Scientific Corp.	5/7/2020	Ratification of Auditor	For



Boston Scientific Corp.	5/7/2020	Shareholder Proposal Regarding Report on Non-Management Employee Representation on the Board	Against
Idexx Laboratories, Inc.	5/6/2020	Elect Rebecca M. Henderson	For
Idexx Laboratories, Inc.	5/6/2020	Elect Lawrence D. Kingsley	For
Idexx Laboratories, Inc.	5/6/2020	Elect Sophie V. Vandebroek	For
Idexx Laboratories, Inc.	5/6/2020	Ratification of Auditor	For
Idexx Laboratories, Inc.	5/6/2020	Advisory Vote on Executive Compensation	For
Gilead Sciences, Inc.	5/6/2020	Elect Jacqueline K. Barton	For
Gilead Sciences, Inc.	5/6/2020	Elect Sandra J. Horning	For
Gilead Sciences, Inc.	5/6/2020	Elect Kelly A. Kramer	For
Gilead Sciences, Inc.	5/6/2020	Elect Kevin E. Lofton	For
Gilead Sciences, Inc.	5/6/2020	Elect Harish Manwani	For
Gilead Sciences, Inc.	5/6/2020	Elect Daniel P. O'Day	For
Gilead Sciences, Inc.	5/6/2020	Elect Richard J. Whitley	For
Gilead Sciences, Inc.	5/6/2020	Elect Per Wold-Olsen	For
Gilead Sciences, Inc.	5/6/2020	Ratification of Auditor	For
Gilead Sciences, Inc.	5/6/2020	Advisory Vote on Executive Compensation	For
Gilead Sciences, Inc.	5/6/2020	Shareholder Proposal Regarding Independent Chair	For
Gilead Sciences, Inc.	5/6/2020	Shareholder Proposal Regarding Reducing Ownership Threshold Required to Act by Written Consent	For
Alexion Pharmaceuticals Inc.	5/13/2020	Elect Felix J. Baker	For
Alexion Pharmaceuticals Inc.	5/13/2020	Elect David R. Brennan	For
Alexion Pharmaceuticals Inc.	5/13/2020	Elect Christopher J. Coughlin	For
Alexion Pharmaceuticals Inc.	5/13/2020	Elect Deborah Dunsire	For
Alexion Pharmaceuticals Inc.	5/13/2020	Elect Paul A. Friedman	For
Alexion Pharmaceuticals Inc.	5/13/2020	Elect Ludwig N. Hantson	For
Alexion Pharmaceuticals Inc.	5/13/2020	Elect John T. Mollen	For
Alexion Pharmaceuticals Inc.	5/13/2020	Elect Francois Nader	For
Alexion Pharmaceuticals Inc.	5/13/2020	Elect Judith A. Reinsdorf	For
Alexion Pharmaceuticals Inc.	5/13/2020	Elect Andreas Rummelt	For
Alexion Pharmaceuticals Inc.	5/13/2020	Ratification of Auditor	For
Alexion Pharmaceuticals Inc.	5/13/2020	Advisory Vote on Executive Compensation	For
Alexion Pharmaceuticals Inc.	5/13/2020	Shareholder Proposal Regarding Right to Call Special Meetings	For
Teleflex Incorporated	5/1/2020	Elect George Babich, Jr.	For
Teleflex Incorporated	5/1/2020	Elect Gretchen R. Haggerty	For
Teleflex Incorporated	5/1/2020	Elect Liam J. Kelly	For
Teleflex Incorporated	5/1/2020	Advisory Vote on Executive Compensation	For
Teleflex Incorporated	5/1/2020	Ratification of Auditor	For
Alkermes plc	5/20/2020	Elect Shane M. Cooke	For
Alkermes plc	5/20/2020	Elect Richard Gaynor	For
Alkermes plc	5/20/2020	Elect Paul J. Mitchell	For
Alkermes plc	5/20/2020	Elect Richard F. Pops	For
Alkermes plc	5/20/2020	Advisory Vote on Executive Compensation	For
Alkermes plc	5/20/2020	Ratification of Auditor	For
Alkermes plc	5/20/2020	Amendment to the 2018 Stock Option and Incentive Plan	For
Zoetis Inc	5/20/2020	Elect Gregory Norden	For
Zoetis Inc	5/20/2020	Elect Louise M. Parent	For
Zoetis Inc	5/20/2020	Elect Kristin C. Peck	For



Zoetis Inc	5/20/2020	Elect Robert W. Scully	For
Zoetis Inc	5/20/2020	Advisory Vote on Executive Compensation	For
Zoetis Inc	5/20/2020	Frequency of Advisory Vote on Executive Compensation	1 Year
Zoetis Inc	5/20/2020	Ratification of Auditor	For
Align Technology, Inc.	5/20/2020	Elect Kevin J. Dallas	For
Align Technology, Inc.	5/20/2020	Elect Joseph M. Hogan	For
Align Technology, Inc.	5/20/2020	Elect Joseph Lacob	For
Align Technology, Inc.	5/20/2020	Elect C. Raymond Larkin, Jr.	For
Align Technology, Inc.	5/20/2020	Elect George J. Morrow	For
Align Technology, Inc.	5/20/2020	Elect Anne Myong	For
Align Technology, Inc.	5/20/2020	Elect Thomas M. Prescott	For
Align Technology, Inc.	5/20/2020	Elect Andrea L. Saia	For
Align Technology, Inc.	5/20/2020	Elect Greg J. Santora	For
Align Technology, Inc.	5/20/2020	Elect Susan E. Siegel	For
Align Technology, Inc.	5/20/2020	Elect Warren S. Thaler	For
Align Technology, Inc.	5/20/2020	Ratification of Auditor	For
Align Technology, Inc.	5/20/2020	Advisory Vote on Executive Compensation	For
Thermo Fisher Scientific Inc.	5/20/2020	Elect Marc N. Casper	For
Thermo Fisher Scientific Inc.	5/20/2020	Elect Nelson J. Chai	For
Thermo Fisher Scientific Inc.	5/20/2020	Elect C. Martin Harris	For
Thermo Fisher Scientific Inc.	5/20/2020	Elect Tyler Jacks	For
Thermo Fisher Scientific Inc.	5/20/2020	Elect Judy C. Lewent	For
Thermo Fisher Scientific Inc.	5/20/2020	Elect Thomas J. Lynch	For
Thermo Fisher Scientific Inc.	5/20/2020	Elect Jim P. Manzi	For
Thermo Fisher Scientific Inc.	5/20/2020	Elect James C. Mullen	For
Thermo Fisher Scientific Inc.	5/20/2020	Elect Lars Rebien Sørensen	For
Thermo Fisher Scientific Inc.	5/20/2020	Elect Debora L. Spar	For
Thermo Fisher Scientific Inc.	5/20/2020	Elect Scott M. Sperling	For
Thermo Fisher Scientific Inc.	5/20/2020	Elect Dion J. Weisler	For
Thermo Fisher Scientific Inc.	5/20/2020	Advisory Vote on Executive Compensation	For
Thermo Fisher Scientific Inc.	5/20/2020	Ratification of Auditor	For
Cerner Corp.	5/22/2020	Elect Julie L. Gerberding	For
Cerner Corp.	5/22/2020	Elect Brent Shafer	For
Cerner Corp.	5/22/2020	Elect William D. Zollars	For
Cerner Corp.	5/22/2020	Ratification of Auditor	For
Cerner Corp.	5/22/2020	Advisory Vote on Executive Compensation	For
Cerner Corp.	5/22/2020	Repeal of Classified Board	For
Cerner Corp.	5/22/2020	Amendment to the Advance Notice Provisions	For
AMGEN Inc.	5/19/2020	Elect Wanda M. Austin	For
AMGEN Inc.	5/19/2020	Elect Robert A. Bradway	For
AMGEN Inc.	5/19/2020	Elect Brian J. Druker	For
AMGEN Inc.	5/19/2020	Elect Robert A. Eckert	For
AMGEN Inc.	5/19/2020	Elect Greg C. Garland	For
AMGEN Inc.	5/19/2020	Elect Fred Hassan	For
AMGEN Inc.	5/19/2020	Elect Charles M. Holley, Jr.	For
AMGEN Inc.	5/19/2020	Elect Tyler Jacks	For
AMGEN Inc.	5/19/2020	Elect Ellen J. Kullman	For
AMGEN Inc.	5/19/2020	Elect Ronald D. Sugar	For
AMGEN Inc.	5/19/2020	Elect R. Sanders Williams	For
AMGEN Inc.	5/19/2020	Advisory Vote on Executive Compensation	For
AMGEN Inc.	5/19/2020	Ratification of Auditor	For



AMGEN Inc.	5/19/2020	Shareholder Proposal Regarding Independent Chair	For
Merck & Co Inc	5/26/2020	Elect Leslie A. Brun	For
Merck & Co Inc	5/26/2020	Elect Thomas R. Cech	For
Merck & Co Inc	5/26/2020	Elect Mary Ellen Coe	For
Merck & Co Inc	5/26/2020	Elect Pamela J. Craig	For
Merck & Co Inc	5/26/2020	Elect Kenneth C. Frazier	For
Merck & Co Inc	5/26/2020	Elect Thomas H. Glöcker	For
Merck & Co Inc	5/26/2020	Elect Risa Lavizzo-Mourey	For
Merck & Co Inc	5/26/2020	Elect Paul B. Rothman	For
Merck & Co Inc	5/26/2020	Elect Patricia F. Russo	For
Merck & Co Inc	5/26/2020	Elect Christine E. Seidman	For
Merck & Co Inc	5/26/2020	Elect Inge G. Thulin	For
Merck & Co Inc	5/26/2020	Elect Kathy J. Warden	For
Merck & Co Inc	5/26/2020	Elect Peter C. Wendell	For
Merck & Co Inc	5/26/2020	Advisory Vote on Executive Compensation	For
Merck & Co Inc	5/26/2020	Ratification of Auditor	For
Merck & Co Inc	5/26/2020	Shareholder Proposal Regarding Right to Act by Written Consent	For
Merck & Co Inc	5/26/2020	Shareholder Proposal Regarding Report on Tax Savings as a Result of the Tax Cut and Jobs Act	Against
Elanco Animal Health Inc	5/21/2020	Elect Michael J. Harrington	For
Elanco Animal Health Inc	5/21/2020	Elect Deborah T. Kochevar	For
Elanco Animal Health Inc	5/21/2020	Elect Kirk McDonald	For
Elanco Animal Health Inc	5/21/2020	Ratification of Auditor	For
Elanco Animal Health Inc	5/21/2020	Advisory Vote on Executive Compensation	For
Dexcom Inc	5/21/2020	Elect Richard A. Collins	For
Dexcom Inc	5/21/2020	Elect Mark G. Foletta	For
Dexcom Inc	5/21/2020	Elect Eric Topol	For
Dexcom Inc	5/21/2020	Ratification of Auditor	For
Dexcom Inc	5/21/2020	Advisory Vote on Executive Compensation	For
Alcon Inc.	5/6/2020	Accounts and Reports	For
Alcon Inc.	5/6/2020	Ratification of Board and Management Acts	For
Alcon Inc.	5/6/2020	Allocation of Profits	For
Alcon Inc.	5/6/2020	Compensation Report	For
Alcon Inc.	5/6/2020	Board Compensation	For
Alcon Inc.	5/6/2020	Executive Compensation	For
Alcon Inc.	5/6/2020	Elect F. Michael Ball as Board Chair	For
Alcon Inc.	5/6/2020	Elect Lynn D. Bleil	For
Alcon Inc.	5/6/2020	Elect Arthur Cummings	For
Alcon Inc.	5/6/2020	Elect David Endicott	For
Alcon Inc.	5/6/2020	Elect Thomas Glanzmann	For
Alcon Inc.	5/6/2020	Elect D. Keith Grossman	For
Alcon Inc.	5/6/2020	Elect Scott H. Maw	For
Alcon Inc.	5/6/2020	Elect Karen J. May	For
Alcon Inc.	5/6/2020	Elect Ines Pöschel	For
Alcon Inc.	5/6/2020	Elect Dieter Späth	For
Alcon Inc.	5/6/2020	Elect Thomas Glanzmann as Compensation Committee Member	For
Alcon Inc.	5/6/2020	Elect D. Keith Grossman as Compensation Committee Member	For



Alcon Inc.	5/6/2020	Elect Karen J. May as Compensation Committee Member	For
Alcon Inc.	5/6/2020	Elect Ines Pöschel as Compensation Committee Member	For
Alcon Inc.	5/6/2020	Appointment of Independent Proxy	For
Alcon Inc.	5/6/2020	Appointment of Auditor	For
Biomarin Pharmaceutical Inc.	5/27/2020	Elect Jean-Jacques Bienaimé	For
Biomarin Pharmaceutical Inc.	5/27/2020	Elect Elizabeth McKee Anderson	For
Biomarin Pharmaceutical Inc.	5/27/2020	Elect Willard H. Dere	For
Biomarin Pharmaceutical Inc.	5/27/2020	Elect Michael Grey	For
Biomarin Pharmaceutical Inc.	5/27/2020	Elect Elaine J. Heron	For
Biomarin Pharmaceutical Inc.	5/27/2020	Elect Robert J. Hombach	For
Biomarin Pharmaceutical Inc.	5/27/2020	Elect V. Bryan Lawlis	For
Biomarin Pharmaceutical Inc.	5/27/2020	Elect Richard A. Meier	For
Biomarin Pharmaceutical Inc.	5/27/2020	Elect David E.I. Pyott	For
Biomarin Pharmaceutical Inc.	5/27/2020	Elect Dennis J. Slamon	For
Biomarin Pharmaceutical Inc.	5/27/2020	Ratification of Auditor	For
Biomarin Pharmaceutical Inc.	5/27/2020	Advisory Vote on Executive Compensation	For
Envista Holdings Corp	5/27/2020	Elect Kieran T. Gallahue	For
Envista Holdings Corp	5/27/2020	Ratification of Auditor	For
Envista Holdings Corp	5/27/2020	Advisory Vote on Executive Compensation	For
Envista Holdings Corp	5/27/2020	Frequency of Advisory Vote on Executive Compensation	1 Year
Illumina Inc	5/27/2020	Elect Caroline D. Dorsa	For
Illumina Inc	5/27/2020	Elect Robert S. Epstein	For
Illumina Inc	5/27/2020	Elect Scott Gottlieb	For
Illumina Inc	5/27/2020	Elect Philip W. Schiller	For
Illumina Inc	5/27/2020	Ratification of Auditor	For
Illumina Inc	5/27/2020	Advisory Vote on Executive Compensation	For
Illumina Inc	5/27/2020	Shareholder Proposal Regarding Political Contributions and Expenditures Report	Against
Neogenomics Inc.	5/28/2020	Elect Douglas M. VanOort	For
Neogenomics Inc.	5/28/2020	Elect Steven C. Jones	For
Neogenomics Inc.	5/28/2020	Elect Kevin C. Johnson	For
Neogenomics Inc.	5/28/2020	Elect Raymond R. Hipp	For
Neogenomics Inc.	5/28/2020	Elect Bruce K. Crowther	For
Neogenomics Inc.	5/28/2020	Elect Lynn A. Tetrault	For
Neogenomics Inc.	5/28/2020	Elect Allison L. Hannah	For
Neogenomics Inc.	5/28/2020	Elect Stephen M. Kanovsky	For
Neogenomics Inc.	5/28/2020	Elect Rachel A. Stahler	For
Neogenomics Inc.	5/28/2020	Advisory Vote on Executive Compensation	For
Neogenomics Inc.	5/28/2020	Ratification of Auditor	For
Biogen Inc	6/3/2020	Elect Alexander J. Denner	For
Biogen Inc	6/3/2020	Elect Caroline D. Dorsa	For
Biogen Inc	6/3/2020	Elect William A. Hawkins	For
Biogen Inc	6/3/2020	Elect Nancy L. Leaming	For
Biogen Inc	6/3/2020	Elect Jesus B. Mantas	For
Biogen Inc	6/3/2020	Elect Richard C. Mulligan	For
Biogen Inc	6/3/2020	Elect Robert W. Pangia	For
Biogen Inc	6/3/2020	Elect Stelios Papadopoulos	For
Biogen Inc	6/3/2020	Elect Brian S. Posner	For
Biogen Inc	6/3/2020	Elect Eric K. Rowinsky	For
Biogen Inc	6/3/2020	Elect Stephen A. Sherwin	For



Biogen Inc	6/3/2020	Elect Michel Vounatsos	For
Biogen Inc	6/3/2020	Ratification of Auditor	For
Biogen Inc	6/3/2020	Advisory Vote on Executive Compensation	For
Sarepta Therapeutics Inc	6/4/2020	Elect Douglas S. Ingram	For
Sarepta Therapeutics Inc	6/4/2020	Elect Hans Wigzell	For
Sarepta Therapeutics Inc	6/4/2020	Elect Mary Ann Gray	For
Sarepta Therapeutics Inc	6/4/2020	Advisory Vote on Executive Compensation	For
Sarepta Therapeutics Inc	6/4/2020	Increase of Authorized Common Stock	For
Sarepta Therapeutics Inc	6/4/2020	Amendment to the 2018 Equity Incentive Plan	For
Sarepta Therapeutics Inc	6/4/2020	Ratification of Auditor	For
Regeneron Pharmaceuticals, Inc.	6/12/2020	Elect N. Anthony Coles	For
Regeneron Pharmaceuticals, Inc.	6/12/2020	Elect Joseph L. Goldstein	For
Regeneron Pharmaceuticals, Inc.	6/12/2020	Elect Christine A. Poon	For
Regeneron Pharmaceuticals, Inc.	6/12/2020	Elect P. Roy Vagelos	For
Regeneron Pharmaceuticals, Inc.	6/12/2020	Elect Huda Y. Zoghbi	For
Regeneron Pharmaceuticals, Inc.	6/12/2020	Ratification of Auditor	For
Regeneron Pharmaceuticals, Inc.	6/12/2020	Amendment to the 2014 Long-Term Incentive Plan	For
Regeneron Pharmaceuticals, Inc.	6/12/2020	Advisory Vote on Executive Compensation	For
Glaukos Corporation	6/3/2020	Elect William J. Link	For
Glaukos Corporation	6/3/2020	Elect Aimee S. Weisner	For
Glaukos Corporation	6/3/2020	Advisory Vote on Executive Compensation	For
Glaukos Corporation	6/3/2020	Ratification of Auditor	For
Incyte Corp.	5/26/2020	Elect Julian C. Baker	For
Incyte Corp.	5/26/2020	Elect Jean-Jacques Bienaimé	For
Incyte Corp.	5/26/2020	Elect Paul J. Clancy	For
Incyte Corp.	5/26/2020	Elect Wendy L. Dixon	For
Incyte Corp.	5/26/2020	Elect Jacquelyn A. Fouse	For
Incyte Corp.	5/26/2020	Elect Paul A. Friedman	For
Incyte Corp.	5/26/2020	Elect Edmund P. Harrigan	For
Incyte Corp.	5/26/2020	Elect Katherine A. High	For
Incyte Corp.	5/26/2020	Elect Hervé Hoppenot	For
Incyte Corp.	5/26/2020	Advisory Vote on Executive Compensation	For
Incyte Corp.	5/26/2020	Amendment to the 1997 Employee Stock Purchase Plan	For
Incyte Corp.	5/26/2020	Ratification of Auditor	For
Incyte Corp.	5/26/2020	Shareholder Proposal Regarding Independent Chair	For
Puma Biotechnology Inc	6/9/2020	Elect Alan H. Auerbach	For
Puma Biotechnology Inc	6/9/2020	Elect Ann C. Miller	For
Puma Biotechnology Inc	6/9/2020	Elect Michael P. Miller	For
Puma Biotechnology Inc	6/9/2020	Elect Jay M. Moyes	For
Puma Biotechnology Inc	6/9/2020	Elect Hugh O'Dowd	For
Puma Biotechnology Inc	6/9/2020	Elect Adrian M. Senderowicz	For
Puma Biotechnology Inc	6/9/2020	Elect Troy E. Wilson	For
Puma Biotechnology Inc	6/9/2020	Elect Frank E. Zavrl	For
Puma Biotechnology Inc	6/9/2020	Ratification of Auditor	For
Puma Biotechnology Inc	6/9/2020	Advisory Vote on Executive Compensation	For
Vertex Pharmaceuticals, Inc.	6/3/2020	Elect Sangeeta N. Bhatia	For
Vertex Pharmaceuticals, Inc.	6/3/2020	Elect Lloyd A. Carney	For
Vertex Pharmaceuticals, Inc.	6/3/2020	Elect Alan M. Garber	For
Vertex Pharmaceuticals, Inc.	6/3/2020	Elect Terrence C. Kearney	For



Vertex Pharmaceuticals, Inc.	6/3/2020	Elect Reshma Kewalramani	For
Vertex Pharmaceuticals, Inc.	6/3/2020	Elect Yuchun Lee	For
Vertex Pharmaceuticals, Inc.	6/3/2020	Elect Jeffrey M. Leiden	For
Vertex Pharmaceuticals, Inc.	6/3/2020	Elect Margaret G. McGlynn	For
Vertex Pharmaceuticals, Inc.	6/3/2020	Elect Diana McKenzie	For
Vertex Pharmaceuticals, Inc.	6/3/2020	Elect Bruce I. Sachs	For
Vertex Pharmaceuticals, Inc.	6/3/2020	Ratification of Auditor	For
Vertex Pharmaceuticals, Inc.	6/3/2020	Advisory Vote on Executive Compensation	For
Vertex Pharmaceuticals, Inc.	6/3/2020	Shareholder Proposal Regarding Lobbying Report	Against
Pacira BioSciences Inc	6/8/2020	Elect Christopher Christie	For
Pacira BioSciences Inc	6/8/2020	Elect Yvonne Greenstreet	For
Pacira BioSciences Inc	6/8/2020	Elect Gary Pace	For
Pacira BioSciences Inc	6/8/2020	Elect David Stack	For
Pacira BioSciences Inc	6/8/2020	Ratification of Auditor	For
Pacira BioSciences Inc	6/8/2020	Advisory Vote on Executive Compensation	For
Immunomedics, Inc.	6/18/2020	Elect Behzad Aghazadeh	For
Immunomedics, Inc.	6/18/2020	Elect Robert Azelby	For
Immunomedics, Inc.	6/18/2020	Elect Charles M. Baum	For
Immunomedics, Inc.	6/18/2020	Elect Scott A. Canute	For
Immunomedics, Inc.	6/18/2020	Elect Barbara G. Duncan	For
Immunomedics, Inc.	6/18/2020	Elect Peter Barton Hutt	For
Immunomedics, Inc.	6/18/2020	Elect Khalid Islam	For
Immunomedics, Inc.	6/18/2020	Elect Harout Semerjian	For
Immunomedics, Inc.	6/18/2020	Advisory Vote on Executive Compensation	For
Immunomedics, Inc.	6/18/2020	Increase of Authorized Common Stock	For
Immunomedics, Inc.	6/18/2020	Amendment to the 2014 Long Term Incentive Plan	For
Immunomedics, Inc.	6/18/2020	Approval of the 2020 Employee Stock Purchase Plan	For
Immunomedics, Inc.	6/18/2020	Ratification of Auditor	For
Veeva Systems Inc	6/25/2020	Elect Mark Carges	For
Veeva Systems Inc	6/25/2020	Elect Paul E. Chamberlain	For
Veeva Systems Inc	6/25/2020	Elect Paul Sekhri	For
Veeva Systems Inc	6/25/2020	Ratification of Auditor	For
Shionogi & Co. Ltd.	6/23/2020	Allocation of Profits/Dividends	For
Shionogi & Co. Ltd.	6/23/2020	Elect Isao Teshirogi	For
Shionogi & Co. Ltd.	6/23/2020	Elect Takuko Sawada	For
Shionogi & Co. Ltd.	6/23/2020	Elect Keiichi Ando	For
Shionogi & Co. Ltd.	6/23/2020	Elect Hiroshi Ozaki	For
Shionogi & Co. Ltd.	6/23/2020	Elect Fumi Takatsuki	For
Shionogi & Co. Ltd.	6/23/2020	Elect Ikuo Kato	For
Shionogi & Co. Ltd.	6/23/2020	Elect Shuichi Okuhara	For
Exact Sciences Corp.	7/23/2020	Elect Eli Casdin	For
Exact Sciences Corp.	7/23/2020	Elect James E. Doyle	For
Exact Sciences Corp.	7/23/2020	Elect Freda C. Lewis-Hall	For
Exact Sciences Corp.	7/23/2020	Elect Kathleen Sebelius	For
Exact Sciences Corp.	7/23/2020	Ratification of Auditor	For
Exact Sciences Corp.	7/23/2020	Advisory Vote on Executive Compensation	For
Exact Sciences Corp.	7/23/2020	Increase in Authorized Common Stock	For
CSL Ltd.	10/14/2020	Re-elect Bruce Brook	For
CSL Ltd.	10/14/2020	Elect Carolyn Hewson	For
CSL Ltd.	10/14/2020	Elect Pascal Soriot	For



CSL Ltd.	10/14/2020	Remuneration Report	For
CSL Ltd.	10/14/2020	Equity Grants (MD/CEO Paul Perreault)	For
Medtronic Plc	12/11/2020	Elect Richard H. Anderson	For
Medtronic Plc	12/11/2020	Elect Craig Arnold	For
Medtronic Plc	12/11/2020	Elect Scott C. Donnelly	For
Medtronic Plc	12/11/2020	Elect Andrea J. Goldsmith	For
Medtronic Plc	12/11/2020	Elect Randall J. Hogan, III	For
Medtronic Plc	12/11/2020	Elect Michael O. Leavitt	For
Medtronic Plc	12/11/2020	Elect James T. Lenehan	For
Medtronic Plc	12/11/2020	Elect Kevin E. Lofton	For
Medtronic Plc	12/11/2020	Elect Geoffrey S. Martha	For
Medtronic Plc	12/11/2020	Elect Elizabeth G. Nabel	For
Medtronic Plc	12/11/2020	Elect Denise M. O'Leary	For
Medtronic Plc	12/11/2020	Elect Kendall J. Powell	For
Medtronic Plc	12/11/2020	Appointment of Auditor and Authority to Set Fees	For
Medtronic Plc	12/11/2020	Advisory Vote on Executive Compensation	For
Medtronic Plc	12/11/2020	Authority to Issue Shares w/ Preemptive Rights	For
Medtronic Plc	12/11/2020	Authority to Issue Shares w/o Preemptive Rights	For
Medtronic Plc	12/11/2020	Authority to Repurchase Shares	For

ALAHLI HEALTHCARE TRADING EQUITY FUND
(Managed by NCB Capital Company)

FINANCIAL STATEMENTS

For the year ended 31 December 2020

with

Independent Auditor's Report to the Unitholders



KPMG Professional Services
Riyadh Front, Airport road
P O Box 92876
Riyadh 11663
Kingdom of Saudi Arabia
Headquarter

Commercial Registration No 1010425494

كي بي إم جي للاستشارات المهنية
واجهة الرياض، طريق المطار
صندوق بريد ٩٢٨٧٦
الرياض ١١٦٦٣
المملكة العربية السعودية
المركز الرئيسي

سجل تجاري رقم ١٠١٠٤٢٥٤٩٤

Independent Auditor's Report

To the Unitholders of AIAhli Healthcare Trading Equity Fund

Opinion

We have audited the financial statements of **AIAhli Healthcare Trading Equity Fund** ("the Fund") managed by NCB Capital Company (the "Fund Manager"), which comprise the statement of financial position as at 31 December 2020, the statements of profit or loss and other comprehensive income, changes in equity attributable to unitholders and cash flows for the year then ended, and notes to the financial statements, comprising significant accounting policies and other explanatory information.

In our opinion, the accompanying financial statements present fairly, in all material respects, the financial position of the Fund as at 31 December 2020, and its financial performance and its cash flows for the year then ended in accordance with International Financial Reporting Standards (IFRS) that are endorsed in the Kingdom of Saudi Arabia and other standards and pronouncements issued by Saudi Organization for Certified Public Accountants (SOCPA).

Basis for Opinion

We conducted our audit in accordance with International Standards on Auditing that are endorsed in the Kingdom of Saudi Arabia. Our responsibilities under those standards are further described in the Auditor's Responsibilities for the Audit of the Financial Statements section of our report. We are independent of the Fund in accordance with the professional code of conduct and ethics that are endorsed in the Kingdom of Saudi Arabia that are relevant to our audit of the financial statements, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Responsibilities of Fund Manager and Those Charged with Governance for the Financial Statements

The Fund Manager is responsible for the preparation and fair presentation of the financial statements in accordance with IFRS that are endorsed in Kingdom of Saudi Arabia and other standards and pronouncements issued by SOCPA and to comply with the applicable provisions of the Investment Funds Regulations issued by the Capital Market Authority ("CMA"), the Fund's terms and conditions and the Information Memorandum, and for such internal control as the Fund Manager determines is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the Fund Manager is responsible for assessing the Fund's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Fund Manager either intends to liquidate the Fund or to cease operations, or has no realistic alternative but to do so.

Those charged with governance, the Fund Board, are responsible for overseeing the Fund's financial reporting process.

Independent Auditor's Report

To the Unitholders of AlAhli Healthcare Trading Equity Fund (continued)

Auditor's Responsibilities for the Audit of the Financial Statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. 'Reasonable assurance' is a high level of assurance, but is not a guarantee that an audit conducted in accordance with International Standards on Auditing that are endorsed in the Kingdom of Saudi Arabia, will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

As part of an audit in accordance with International Standards on Auditing that are endorsed in the Kingdom of Saudi Arabia, we exercise professional judgement and maintain professional scepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Fund's internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Fund Manager.
- Conclude on the appropriateness of the Fund Manager's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Fund's ability to continue as a going concern. If we conclude that a material uncertainty exists, then we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Fund to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit of **AlAhli Healthcare Trading Equity Fund** ("the Fund").

For KPMG Professional Services



Dr. Abdullah Hamad Al Fozan
License No. 348

Riyadh: 19 Sha'ban 1442H
Corresponding to 1 April 2021



ALAHLI HEALTHCARE TRADING EQUITY FUND
(Managed by NCB Capital Company)

STATEMENT OF FINANCIAL POSITION

As at 31 December 2020

Expressed in US Dollars '000 (unless otherwise stated)

		31 December 2020	31 December 2019
	<i>Notes</i>		
ASSETS			
Cash and cash equivalents	8	2,297	2,207
Investments	9	69,702	58,165
Other receivables		863	85
Total assets		72,862	60,457
LIABILITY			
Other payables		275	296
Equity attributable to Unitholders		72,587	60,161
Units in issue in thousands (number)	10	23,042	22,177
Equity per unit (USD)		3.1502	2.7128

The accompanying notes 1 to 14 form
an integral part of these financial statements

ALAHLI HEALTHCARE TRADING EQUITY FUND
(Managed by NCB Capital Company)

STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME

For the year ended 31 December 2020

Expressed in US Dollars '000 (unless otherwise stated)

	<i>Note</i>	For the year ended 31 December	
		<u>2020</u>	<u>2019</u>
Dividend income		699	663
Realised gain on sale on FVTPL investments		1,998	2,993
Unrealised gain on FVTPL investments		8,480	8,039
Total income		11,177	11,695
Management fees	11	(1,162)	(997)
Value added tax		(137)	(52)
Administrative expenses		(15)	(16)
Professional fees		(10)	(9)
Shariah audit fees		(8)	(7)
Fund Board remuneration		(6)	(6)
Custody fees		(5)	(6)
Capital market authority fees		(2)	(2)
Total operating expenses		(1,345)	(1,095)
Profit for the year		9,832	10,600
Other comprehensive income for the year		--	--
Total comprehensive income for the year		9,832	10,600

The accompanying notes 1 to 14 form
an integral part of these financial statements

ALAHLI HEALTHCARE TRADING EQUITY FUND
(Managed by NCB Capital Company)

STATEMENT OF CHANGES IN EQUITY ATTRIBUTABLE TO UNITHOLDERS

For the year ended 31 December 2020

Expressed in US Dollars '000 (unless otherwise stated)

	For the year ended 31 December	
	<u>2020</u>	<u>2019</u>
Equity attributable to Unitholders at the beginning of the year	60,161	47,875
Total comprehensive income for the year	9,832	10,600
Increase in equity from unit transactions during the year		
Proceeds from units sold	10,616	8,663
Value of units redeemed	(8,022)	(6,977)
	<u>2,594</u>	<u>1,686</u>
Equity attributable to Unitholders at the end of the year	<u><u>72,587</u></u>	<u><u>60,161</u></u>

The accompanying notes 1 to 14 form
an integral part of these financial statements

ALAHLI HEALTHCARE TRADING EQUITY FUND
(Managed by NCB Capital Company)

STATEMENT OF CASH FLOWS

For the year ended 31 December 2020

Expressed in US Dollars '000 (unless otherwise stated)

	<i>Note</i>	For the year ended	
		31 December	
		2020	2019
Cash flow from operating activities		9,832	10,600
Profit for the year			
<i>Adjustment for:</i>			
Realized gain on FVTPL investments		(1,998)	(2,993)
Unrealized gain on FVTPL investments		(8,480)	(8,039)
		(646)	(432)
Changes in operating assets and liabilities:			
FVTPL investments		(1,059)	(270)
Other receivables		(778)	38
Other payables		(21)	199
Net cash used in operating activities		(2,504)	(465)
Cash flow from financing activities			
Proceeds from units sold		10,616	8,663
Value of units redeemed		(8,022)	(6,977)
Net cash generated from financing activities		2,594	1,686
Increase in cash and cash equivalents		90	1,221
Cash and cash equivalents at the beginning of the year	8	2,207	986
Cash and cash equivalents at the end of the year	8	2,297	2,207

The accompanying notes 1 to 14 form
an integral part of these financial statements

ALAHLI HEALTHCARE TRADING EQUITY FUND
(Managed by NCB Capital Company)

NOTES TO THE FINANCIAL STATEMENTS

For the year ended 31 December 2020

Expressed in US Dollars '000 (unless otherwise stated)

1. THE FUND AND ITS ACTIVITIES

AlAhli Healthcare Trading Equity Fund (the “Fund”) is a Shariah compliant, open-ended investment fund, managed by NCB Capital Company (the “Fund Manager”), a subsidiary of The National Commercial Bank (the “Bank”), for the benefit of the Fund’s Unitholders. The Fund is established under article 30 of the Investment Fund Regulations (the Regulations) issued by the Capital Market Authority (CMA).

As defined in Capital Market Authority’s (CMA) Regulation No. 2-83-2005 dated 21 Jumada Awal 1426H (28 June 2005) the Fund Manager conducts following securities’ activities:

- a) Dealing;
- b) Arranging;
- c) Managing;
- d) Advising; and
- e) Custody;

The Fund’s investments are held by Northern Trust, a custodian appointed by the Fund Manager.

The Fund Manager has appointed an international investment house, TCW Asset Management Company, United States of America as sub-manager to the Fund. Their duties include opening separate independent investment accounts and managing the Fund assets in line with the investment strategies and Shariah guidelines.

The Fund invests in securities of companies involved in healthcare services and related activities, listed on major international stock exchanges and complying with Shariah Principles for investment. Un-invested cash balances may be placed in Murabaha transactions.

The terms and conditions of the Fund were originally approved by the Saudi Central Bank (SAMA) and subsequently endorsed by CMA through its letter dated 18 Dhul Hijja 1429H (corresponding to 16 December 2008). The Fund commenced its activities on 30 October 2000.

The Fund is governed by the Regulations issued by the CMA pursuant to resolution number 1-219-2006 dated 3 Dhul Hijja 1427H (corresponding to 24 December 2006) as amended by the Resolution No 1/61/2016 of Board of the CMA dated 16 Sha’ban 1437H (corresponding to 23 May 2016), which provided detailed requirements for all funds within the Kingdom of Saudi Arabia.

2. BASIS OF ACCOUNTING

These financial statements of the Fund have been prepared in accordance with International Financial Reporting Standards (“IFRS”) as endorsed in the Kingdom of Saudi Arabia and other standards and pronouncements issued by Saudi Organization for Certified Public Accountants (“SOCPA”), and to comply with the applicable provisions of the Investment Funds Regulations issued by Capital Market Authority, the Fund’s terms and conditions and the Information Memorandum.

ALAHLI HEALTHCARE TRADING EQUITY FUND
(Managed by NCB Capital Company)

NOTES TO THE FINANCIAL STATEMENTS

For the year ended 31 December 2020

Expressed in US Dollars '000 (unless otherwise stated)

3. BASIS OF MEASUREMENT

The financial statements have been prepared on a historical cost convention using accrual basis of accounting and going concern concept except for investments measured at fair value through profit or loss ("FVTPL") which are recorded at fair value.

The Fund does not have a clearly identifiable operating cycle and therefore does not present current and non-current assets and liabilities separately in the statement of financial position. Instead, assets and liabilities are presented in order of their liquidity.

4. FUNCTIONAL AND PRESENTATION CURRENCY

Items included in the financial statements are measured using the currency of the primary economic environment in which the Fund operates (the "functional currency"). These financial statements are presented in United States Dollar ("USD") which is the Fund's functional and presentation currency.

5. CHANGES IN FUND'S TERMS AND CONDITIONS

There is no change in the terms and conditions of the Fund during 2020.

6. CRITICAL ACCOUNTING ESTIMATES AND ASSUMPTIONS

The preparation of the financial statements requires management to make judgments, estimates and assumptions that affect the application of accounting policies and the reported amounts of assets, liabilities, income and expenses. Actual results may differ from these estimates. Estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the year in which the estimates are revised and in any future years affected.

Fair value estimation

Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The fair value measurement is based on the presumption that the transaction to sell the asset or transfer the liability takes place either:

- In the principal market for the asset or liability, or
- In the absence of a principal market, in the most advantageous market for the asset or liability

When available, the Fund measures the fair value of an instrument using the quoted price in an active market for that instrument. A market is regarded as active if transactions for the asset or liability take place with sufficient frequency and volume to provide pricing information on an ongoing basis. The Fund measures instruments quoted in an active market at a market price, because this price reasonable approximation of the exit price.

If there is no quoted price in an active market, then the Fund uses valuation techniques that maximise the use of relevant observable inputs and minimise the use of unobservable inputs. The chosen valuation technique incorporates all of the factors that market participants would take into account in pricing a transaction. The Fund recognizes transfer between levels of fair value at the end of the reporting year during which the change has occurred.

ALAHLI HEALTHCARE TRADING EQUITY FUND
(Managed by NCB Capital Company)

NOTES TO THE FINANCIAL STATEMENTS

For the year ended 31 December 2020

Expressed in US Dollars '000 (unless otherwise stated)

6. CRITICAL ACCOUNTING ESTIMATES AND ASSUMPTIONS (CONTINUED)

The fair value hierarchy has the following levels:

- Level 1 inputs are quoted prices (unadjusted) in active markets for identical assets or liabilities that the entity can access at the measurement date;
- Level 2 inputs are inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly; and
- Level 3 inputs are unobservable inputs for the asset or liability.

The fund has classified the investment measured at Fair Value Through Profit or Loss (FVTPL) per the fair value hierarchy as level 1. During the year there has been no transfer in fair value hierarchy for FVTPL investments. Other financial instruments such as cash and cash equivalents, other receivables and other payables are short term in nature and their carrying values approximate fair value.

7. SIGNIFICANT ACCOUNTING POLICIES

The principal accounting policies applied in the preparation of these financial statements are set out below. These policies have been consistently applied to all the years presented, unless otherwise stated. A number of new standards are effective from 1 January 2020 but they do not have a material effect on the Fund's financial statements.

7.1 *Cash and cash equivalents*

Cash equivalents include cash at bank and short term, highly liquid investments that are readily convertible to known amounts of cash and which are subject to an insignificant risk of change in value. Cash and cash equivalents include bank balances.

7.2 *Receivables*

Receivables are initially recognised when they are originated. Receivables without a significant financing component is initially measured at the transaction price and subsequently at their amortised cost using effective interest / commission rate method. Loss allowance for receivables is always measured at an amount equal to lifetime expected credit losses. Receivables without a significant financing component is initially measured at the transaction price.

7.3 *Financial assets and liabilities*

Classification of financial assets

On initial recognition, a financial asset is measured at its fair value and classified at amortized cost, fair value through profit or loss ("FVTOCI") or fair value through other comprehensive income ("FVOCI").

Financial asset at amortized cost

A financial asset is measured at amortized cost if it meets both of the following conditions and is not designated as at FVTPL:

- the asset is held within a business model whose objective is to hold assets to collect contractual cash flows; and
- the contractual terms of the financial asset give rise on specified dates to cash flows that are solely payments of principal and commission on the principal amount outstanding.

ALAHLI HEALTHCARE TRADING EQUITY FUND
(Managed by NCB Capital Company)

NOTES TO THE FINANCIAL STATEMENTS

For the year ended 31 December 2020

Expressed in US Dollars '000 (unless otherwise stated)

7. SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

7.3 *Financial assets and liabilities (continued)*

Classification of financial assets (continued)

Financial asset at fair value through other comprehensive income ("FVOCI")

A financial asset is measured at FVOCI only if it meets both of the following conditions and is not designated as at FVTPL.

- it is held within a business model whose objective is achieved by both collecting contractual cash flows and selling financial assets; and
- its contractual terms give rise on specified dates to cash flows that are solely payments of principle and commission on the principle amount outstanding.

On initial recognition of an equity investment that is not held for trading, the Fund Manager may irrevocably elect to present subsequent changes in fair value in OCI. This election is made on an investment-by-investment basis.

Financial asset at fair value through profit or loss ("FVTPL")

All financial assets not classified as measured at amortized cost or FVOCI are measure at FVTPL.

Business model assessment

The Fund Manager assesses the objective of a business model in which an asset is held at a portfolio level because this best reflects the way the business is managed and information is provided to management. The information considered includes:

- the stated policies and objectives for the portfolio and the operation of those policies in practice;
- how the performance of the portfolio is evaluated and reported to the Fund Manager;
- the risks that affect the performance of the business model (and the financial assets held within that business model) and how those risks are managed;
- how managers of the business are compensated- e.g. whether compensation is based on the fair value of the assets managed or the contractual cash flows collected; and
- the frequency, volume and timing of sales in prior periods, the reasons for such sales and its expectations about future sales activity. However, information about sales activity is not considered in isolation, but as part of an overall assessment of how the Fund's stated objective for managing the financial assets is achieved and how cash flows are realized.

The business model assessment is based on reasonably expected scenarios without taking 'worst case' or 'stress case' scenarios into account. If cash flows after initial recognition are realized in a way that is different from the Fund's original expectations, the Fund does not change the classification of the remaining financial assets held in that business model, but incorporates such information when assessing newly purchased financial assets going forward.

Financial assets that are held for trading and whose performance is evaluated on a fair value basis are measured at FVTPL because they are neither held to collect contractual cash flows nor held both to collect contractual cash flows and to sell financial assets.

ALAHLI HEALTHCARE TRADING EQUITY FUND
(Managed by NCB Capital Company)

NOTES TO THE FINANCIAL STATEMENTS

For the year ended 31 December 2020

Expressed in US Dollars '000 (unless otherwise stated)

7. SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

7.3 *Financial assets and liabilities (continued)*

Classification of financial assets (continued)

Assessment whether contractual cash flows are solely payments of principal and commission

For the purposes of this assessment, 'Principal' is defined as the fair value of the financial asset on initial recognition. Interest or 'Commission' is defined as consideration for the time value of money and for the credit risk associated with the principal amount outstanding during a particular period of time and for other basic lending risks and costs (for example: liquidity risk and administrative costs), as well as profit margin.

In assessing whether the contractual cash flows are solely payments of principal and commission, the Fund considers the contractual terms of the instrument. This includes assessing whether the financial asset contains a contractual term that could change the timing or amount of contractual cash flows such that it would not meet this condition. In making the assessment, the Fund considers:

- contingent events that would change the amount and timing of cash flows;
- leverage features;
- prepayment and extension terms;
- terms that limit the Fund's claim to cash flows from specified assets (e.g. non-recourse asset arrangements); and
- features that modify consideration of the time value of money – e.g. periodical reset of interest / commission rates.

Reclassifications

Financial assets are not reclassified subsequent to their initial recognition, except in the period after the Fund changes its business model for managing financial assets.

Classification of financial liabilities

The Fund classifies its financial liabilities at amortised cost unless it has designated liabilities at FVTPL.

Recognition and initial measurement

Financial assets at FVTPL are initially recognized on the trade date, which is the date on which the Fund becomes a party to the contractual provisions of the instrument. Other financial assets and financial liabilities are recognized on the date on which they are originated. Financial asset or financial liability is measured initially at fair value plus, for an item not at FVTPL, transaction costs that are directly attributable to its acquisition issue.

Subsequent measurement

Financial assets at FVTPL are subsequently measured at fair value. Net gain or losses including any foreign exchange gains and losses, are recognized in profit or loss in 'gains / (losses) on investments, net' in the statement of comprehensive income.

ALAHLI HEALTHCARE TRADING EQUITY FUND
(Managed by NCB Capital Company)

NOTES TO THE FINANCIAL STATEMENTS

For the year ended 31 December 2020

Expressed in US Dollars '000 (unless otherwise stated)

7. SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

7.3 *Financial assets and liabilities (continued)*

Subsequent measurement (continued)

Financial assets and financial liabilities at amortized cost are subsequently measured at amortized cost using the effective interest / commission method and is recognized in the statement of comprehensive income. Any gain or loss on de-recognition is also recognized in the statement of comprehensive income. The 'amortized cost' of a financial asset or financial liability is the amount at which the financial asset or financial liability is measured on initial recognition minus the principle repayments, plus or minus the cumulative interest / commission using the effective interest / commission method of any difference between that initial amount and the maturity amount and, for financial assets, adjusted for any loss allowance.

Derecognition

The Fund derecognizes a financial asset when the contractual rights to the cash flow from the asset expire, or it transfers the rights to receive the contractual cash flows in a transaction in which substantially all of the risks and rewards of ownership of the financial asset are transferred or in which the Fund neither transfers nor retains substantially all of the risks and rewards of ownership and does not retain control of the financial asset.

On derecognition of the financial asset, the difference between the carrying amount of the asset (or the carrying amount allocated to the portion of the asset that is derecognised) and the consideration received (including any new asset obtained less any new liability assumed) is recognized in statement of comprehensive income. Any commission in such transferred financial assets that is created or retained by the Fund is recognized as a separate asset or liability.

The Fund enters into transactions whereby it transfers assets recognized on its statement of financial position but retains either all or substantially all of the risks and rewards of the transferred assets or a portion of them. If all or substantially all of the risk and rewards are retained, then the transferred assets are not derecognized. The Fund derecognize a financial liability when its contractual obligations are discharged or cancelled or expire.

Offsetting

Financial assets and financial liabilities are offset and the net amount presented in the statement of financial position when, and only when, the Fund has legally enforceable right to offset the amounts and intends either to settle them on a net basis or to realize the asset and settle their liability simultaneously.

Income and expenses are presented on a net basis for gain and losses from financial instruments at FVTPL and foreign exchange gains and losses.

7.4 *Provisions*

A provision is recognised when the Fund has a present legal or constructive obligation as a result of past events, it is probable that an outflow of resources embodying economic benefits will be required to settle the obligation, and a reliable estimate of the amount can be made. Provision is not recognised for future operating loss.

ALAHLI HEALTHCARE TRADING EQUITY FUND
(Managed by NCB Capital Company)

NOTES TO THE FINANCIAL STATEMENTS

For the year ended 31 December 2020

Expressed in US Dollars '000 (unless otherwise stated)

7. SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

7.5 *Equity per unit*

The Fund is open for subscription and redemption of units on every Saudi business day. The equity per unit is calculated by dividing the equity attributable to unitholders included in the statement of financial position by the number of units outstanding at the year end.

7.6 *Distributions to the Unitholders*

Distribution to the Unitholders is accounted for as a deduction from equity attributable to the Unitholders.

7.7 *Units in issue*

The Fund classified financial instruments issued as financial liabilities or equity instruments in accordance with the substance of the contractual terms of the instruments.

The Fund has redeemable units in issue. On liquidation of the Fund, they entitle the holders to the residual net assets. They rank pari passu in all respects and have identical terms and conditions. The redeemable units provide investors with the right to require redemption for cash at a value proportionate to the investor's share in the Fund's net assets at each redemption date as well as in the event of the Fund's liquidation.

Redeemable units are classified as equity as it meets all of the following conditions:

- it entitles the holder to a pro rata share of the Fund's net assets in the event of the Fund's liquidation;
- it is in the class of instruments that is subordinate to all other classes of instruments;
- all financial instruments in the class of instruments that is subordinate to all other classes of instruments have identical features;
- the instrument does not include any other features that would require classification as a liability; and
- the total expected cash flows attributable to the instrument over its life are based substantially on the profit or loss, the change in recognized net assets or the change in the fair value of the recognized and unrecognized net assets of the Fund over the life of the instrument.

Incremental costs directly attributable to the issue or redemption of redeemable units are recognized directly in equity as a deduction from the proceeds or part of the acquisition cost.

7.8 *Taxation / zakat*

Under the current system of zakat and income tax in the Kingdom of Saudi Arabia, the Fund is exempt from paying any zakat and income tax. Zakat and income tax are considered to be the obligation of the Unitholders and are not provided in the financial statements.

The Value Added Tax ("VAT") applicable for fees and expenses are recognized in the statement of comprehensive income.

7.9 *Dividend income*

Dividend income is recognized in statement of comprehensive income on the date on which the right to receive payment is established. For quoted equity securities, this is usually the ex-dividend date. For unquoted equity securities, this is usually the date on which the shareholders approve the payment of a dividend. Dividend income from equity securities designated as at fair value through profit or loss ("FVTPL") is recognized in statement of comprehensive income in a separate line item.

ALAHLI HEALTHCARE TRADING EQUITY FUND
(Managed by NCB Capital Company)

NOTES TO THE FINANCIAL STATEMENTS

For the year ended 31 December 2020

Expressed in US Dollars '000 (unless otherwise stated)

7. SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

7.10 *Management fee expense*

Management fee expense is recognized in the statement of comprehensive income as the related services are performed.

7.11 *Accrued expenses and other payables*

Accrued expenses and other payables are recognised initially at fair value and subsequently measured at amortised cost using the effective commission rate method.

7.12 *New IFRS standards, IFRIC interpretations and amendments thereof, adopted by the Fund*

Below amendments to accounting standards and interpretations became applicable for annual reporting periods commencing on or after 1 January 2020. The Fund manager has assessed that the amendments have no significant impact on the Fund's financial statements.

Standards / Interpretations and Amendments

Amendments to IFRS 3 - Definition of a Business

Amendments to IAS 1 and IAS 8 - Definition of Material

Amendments to References to the Conceptual Framework in IFRS Standards

Amendments to IFRS 9, IAS 39 and IFRS 7 - Interest Rate Benchmark Reform – Phase 1

7.13 *Standards issued but not yet effective*

Standards issued but not yet effective up to the date of issuance of the Fund's financial statements are listed below. The Fund intends to adopt these standards when they become effective.

<u>Standards / Interpretations and amendments</u>	<u>Description</u>	<u>Effective from periods beginning on or after the following date</u>
Amendments to IFRS 16	COVID-19 – Related Rent Concessions	June 1, 2020
IFRS 17	Insurance contracts	January 1, 2023
Amendments to IAS 1	Classification of Liabilities as Current or Non-current	January 1, 2022
Amendments to IAS 37	Onerous contracts – Cost of Fulfilling a contract	January 1, 2022
Amendments to IFRS 9, IAS 39, IFRS 7, IFRS 4 and IFRS 16	Interest Rate Benchmark Reform – Phase 2	January 1, 2021
Amendments to IAS 16	Property, Plant and Equipment: Proceeds before Intended Use	January 1, 2022
Amendments to IFRS 3	Reference to Conceptual Framework	January 1, 2022

The above amended standards and interpretations are not expected to have a significant impact on the Fund's financial statements.

ALAHLI HEALTHCARE TRADING EQUITY FUND
(Managed by NCB Capital Company)

NOTES TO THE FINANCIAL STATEMENTS

For the year ended 31 December 2020

Expressed in US Dollars '000 (unless otherwise stated)

7.13 Standards issued but not yet effective (Continued)

Furthermore, the Capital Market Authority, on March 1, 2021, has issued certain amendments to the Investment Funds Regulations and Glossary of Defined Terms Used in the Regulations and Rules of the Capital Market Authority. These amendments have effective dates starting from May 1, 2021. The Fund Manager is currently in the process of evaluating the impact, if any, of these amendments on the Fund's financial statements.

8. CASH AND CASH EQUIVALENTS

This comprises of balances held with a local Bank having a sound credit rating.

9. INVESTMENTS

INVESTMENTS MEASURED AT FAIR VALUE THROUGH PROFIT OR LOSS

The composition of investments measured at FVTPL by currency is summarized below:

		<i>31 December 2020</i>		
<u>Currency</u>	<u>Country</u>	<u>% of Total Value</u>	<u>Cost</u>	<u>Fair Value</u>
United States Dollar	United States of America and Ireland	76.15	34,869	53,074
Swiss Franc	Switzerland	10.06	5,575	7,014
Japanese Yen	Japan	3.64	1,096	2,536
Danish Krone	Denmark	3.22	1,587	2,244
Pound Sterling	United Kingdom	2.98	1,536	2,077
Euro	France	2.70	1,696	1,883
Australian Dollar	Australia	1.25	536	874
		100	46,895	69,702

		<i>31 December 2019</i>		
<u>Currency</u>	<u>Country</u>	<u>% of Total Value</u>	<u>Cost</u>	<u>Fair Value</u>
United States Dollar	United States of America, Ireland	72.56	31,303	42,205
Swiss Franc	Switzerland	11.49	5,575	6,684
Pound Sterling	United Kingdom	3.60	1,536	2,091
Euro	France	3.38	1,696	1,967
Japanese Yen	Japan	3.30	1,096	1,922
Danish Krone	Denmark	3.20	1,587	1,859
Australian Dollar	Australia	1.33	536	775
Swedish Krona	Sweden	1.14	509	662
		100	43,838	58,165

ALAHLI HEALTHCARE TRADING EQUITY FUND
(Managed by NCB Capital Company)

NOTES TO THE FINANCIAL STATEMENTS

For the year ended 31 December 2020

Expressed in US Dollars '000 (unless otherwise stated)

10. UNITS TRANSACTIONS

Transactions in units during the year are summarized as follows:

	For the year ended 31 December	
	<u>2020</u>	<u>2019</u>
	<u>Units' 000</u>	<u>Units' 000</u>
Units at the beginning of the year	22,177	21,453
Units sold	3,693	3,578
Units redeemed	(2,828)	(2,854)
Net increase in units during the year	865	724
Units at the end of the year	23,042	22,177

As at 31 December 2020, the top five Unitholders represented of 75.33% (31 December 2019: 76.81 %) of the Fund's units.

11. RELATED PARTY TRANSACTIONS AND BALANCES

Parties are considered to be related if one party has the ability to control the other party or exercise significant influence over the other party in making financial or operational decisions. The related parties of the Fund include the Fund Manager, other funds managed by the Fund Manager and Parent of the Fund Manager.

Name of entity

Relationship

NCB Capital Company (NCBC)
National Commercial Bank (NCB)

Fund Manager
Shareholder of the Fund Manager

Management fee and other expenses

The Fund is managed and administered by the Fund Manager. For these services, the Fund accrues, daily a management fee, as determined by the Fund Manager, which should not be more than the maximum annual rate of 1.85% p.a. of the Fund's daily equity as set out in the Fund's terms and conditions.

The Fund Manager is also entitled to recover expenses incurred on behalf of the Fund relating to audit, custody, advisory, data processing and other similar charges. The maximum amount of such expenses that can be recovered from the Fund by the Fund Manager is restricted to 0.5% per annum of the Fund's equity at the respective valuation days. These expenses have been recovered by the Fund Manager on an actual basis.

Transactions with related parties

During the year, the Fund entered into the following transactions, other than those disclosed elsewhere in the financial statements, with related parties in the ordinary course of business. These transactions were carried out on the basis of approved terms and conditions of the Fund. All related party transactions are approved by the Fund Board.

ALAHLI HEALTHCARE TRADING EQUITY FUND
(Managed by NCB Capital Company)

NOTES TO THE FINANCIAL STATEMENTS

For the year ended 31 December 2020

Expressed in US Dollars '000 (unless otherwise stated)

11. RELATED PARTY TRANSACTIONS AND BALANCES (CONTINUED)

Transactions with related parties (continued)

<u>Related party</u>	<u>Nature of transaction</u>	<u>Amount of transactions</u>	
		<u>2020</u>	<u>2019</u>
NCB Capital Company	Management fee	<u>1,162</u>	<u>997</u>
	Expenses paid on behalf of the Fund	<u>183</u>	<u>98</u>

12. FINANCIAL RISK MANAGEMENT

12.1 Financial risk factors

The Fund's activities expose it to a variety of financial risks including market risk, credit risk, liquidity risk and operational risk.

The Fund Manager is responsible for identifying and controlling risks. The Fund Board supervises the Fund Manager and is ultimately responsible for the overall management of the Fund.

Monitoring and controlling risks is primarily set up to be performed based on the limits established by the Fund Board. The Fund has its Terms and Conditions document that set out its overall business strategies, its tolerance of risks and its general risk management philosophy and is obliged to take actions to rebalance the portfolio in line with the investment guidelines.

12.1.1 Market risk

'Market Risk' is the risk that changes in market prices – such as commission rates, foreign exchange rates, equity prices and credit spreads – will affect the Fund's income or the fair value of its holdings in financial instruments.

a) Foreign exchange risk

Foreign exchange risk is the risk that the value of future cash flows of a financial instrument will fluctuate due to changes in foreign exchange rates and arises from financial instruments denominated in foreign currency. The Fund views the United States Dollar as its functional currency.

The Fund's financial assets and liabilities are denominated in currencies other than its functional currency. Accordingly, the value of the Fund's assets may be affected favorably or unfavorably by fluctuations in currency rates.

The analysis calculates the effect of a reasonably possible movement of the U.S. Dollar against the underlying currencies of the investment portfolio with all other variables held constant, on the statement of comprehensive income due to the fair value of currency sensitive assets.

ALAHLI HEALTHCARE TRADING EQUITY FUND
(Managed by NCB Capital Company)

NOTES TO THE FINANCIAL STATEMENTS

For the year ended 31 December 2020

Expressed in US Dollars '000 (unless otherwise stated)

12. FINANCIAL RISK MANAGEMENT (CONTINUED)

12.1. Financial risk factors (continued)

12.1.1 Market risk (continued)

	Change in market rates	31 December <u>2020</u>	31 December <u>2019</u>
Swiss Franc	± 10%	± 701	± 668
Japanese Yen	± 10%	± 254	± 192
Danish Krone	± 10%	± 224	± 186
Pound Sterling	± 10%	± 208	± 209
Euro	± 10%	± 188	± 197
Australian Dollar	± 10%	± 88	± 78
Swedish Krona	± 10%	± --	± 66

b) Price risk

Price risk is the risk that the value of the Fund's financial instruments will fluctuate as a result of changes in market prices caused by factors other than foreign currency and commission rate movements. The price risk arises primarily from uncertainty about the future prices of financial instruments that the Fund holds. The Fund closely monitors the price movement of its investments in financial instruments. As of the statement of financial position date, the Fund has investments in equities.

The effect on the equity (as a result of the change in the fair value of investments) due to a reasonably possible change in equity of the Investee Fund, with all other variables held constants is as follows:

	31 December <u>2020</u>	31 December <u>2019</u>
Effect on equity	±10% <u>6,970</u>	±10% <u>± 5,817</u>

12.1.2 Credit risk

Credit risk is the risk that one party to a financial instrument will fail to discharge an obligation and cause the other party to incur a financial loss. The Fund Manager seeks to manage credit risk by monitoring credit exposures, limiting transactions with specific counterparties, and continually assessing the creditworthiness of counterparties. As at the statement of financial position date, the Fund's maximum exposure to credit risk is represented by the carrying amount of cash and cash equivalents, which represent cash at bank with a local Bank having Moody's credit rating of A3 and other receivable. There is no impact of ECL on these financial assets.

12.1.3 Liquidity risk

Liquidity risk is the risk that the Fund may not be able to generate sufficient cash resources to settle its obligations in full as they fall due or can only do so on terms that are materially disadvantageous.

ALAHLI HEALTHCARE TRADING EQUITY FUND
(Managed by NCB Capital Company)

NOTES TO THE FINANCIAL STATEMENTS

For the year ended 31 December 2020

Expressed in US Dollars '000 (unless otherwise stated)

12 FINANCIAL RISK MANAGEMENT (continued)

12.1. Financial risk factors (continued)

12.1.3 Liquidity risk (continued)

The Fund's terms and conditions provide for subscription and redemption of units on every Saudi and US Business day and it is, therefore, exposed to the liquidity risk of meeting unitholder redemptions on these days. The Fund Manager monitors liquidity requirements by ensuring that sufficient funds are available to meet any commitments as they arise, either through new subscriptions, liquidation of the investment portfolio or by taking short term loans obtained by the Fund Manager. The Fund manages its liquidity risk by investing predominantly in securities that it expects to be able to liquidate within short period.

12.1.4 Operational risk

Operational risk is the risk of direct or indirect loss arising from a variety of causes associated with the processes, technology and infrastructure supporting the Fund's activities either internally or externally at the Fund's service provider and from external factors other than credit, liquidity, currency and market risks such as those arising from the legal and regulatory requirements.

The Fund's objective is to manage operational risk to balance limiting of financial losses and damage to its reputation with achieving its investment objective of generating returns to unitholders.

The primary responsibility for the development and implementation of control over operational risks rests with the Risk Management Team. This responsibility is supported by the development of overall standard for the management of operational risk, which encompasses the controls and processes at the service providers and the establishment of service levels with the service providers, in the following areas:

- documentation of controls and procedures;
- requirements for:
 - appropriate segregation of duties between various functions, roles and responsibilities;
 - reconciliation and monitoring of transactions; and
 - periodic assessment of operational risks faced.
- the adequacy of controls and procedures to address the risks identified;
- compliance with regulatory and other legal requirements;
- development of contingency plans;
- training and professional development;
- ethical and business standards; and
- risk mitigation.

ALAHLI HEALTHCARE TRADING EQUITY FUND
(Managed by NCB Capital Company)

NOTES TO THE FINANCIAL STATEMENTS

For the year ended 31 December 2020

Expressed in US Dollars '000 (unless otherwise stated)

12 FINANCIAL RISK MANAGEMENT (continued)

12.1.5 Considerations due to covid-19

The COVID-19 pandemic continues to disrupt global markets as many geographies are experiencing a “second wave” of infections despite having previously controlled the outbreak through aggressive precautionary measures such as imposing restrictions on travel, lockdowns and strict social distancing rules. The Government of the Kingdom of Saudi Arabia (“the Government”) however has managed to successfully control the outbreak to date, owing primarily to the unprecedented yet effective measures taken by the Government, following which the Government has ended the lockdowns and has taken phased measures towards normalization.

Recently, a number of COVID-19 vaccines have been developed and approved for mass distribution by various governments around the world. The Government has also approved a vaccine which is currently available for healthcare workers and certain other categories of people and it will be available to the masses in general during 2021. Despite the fact that there are some uncertainties around the COVID-19 vaccine such as how long the immunity last, whether vaccine will prevent transmission or not etc.; however, the testing results showed exceptionally high success rates. Hence, the Fund continues to be cognizant of both the micro and macroeconomic challenges that COVID-19 has posed, the teething effects of which may be felt for some time and is closely monitoring its exposures.

13 LAST VALUATION DAY

The last valuation day for the purpose of preparation of these financial statements was 31 December 2020 (2018: 31 December 2019).

14 APPROVAL OF THE FINANCIAL STATEMENTS

These financial statements were approved by the Fund Manager 19 Sha’ban 1442H corresponding to 1 April 2021.